glycine has been researched along with Schizophrenia in 186 studies
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Current literature supported by preclinical and clinical provides substantial evidence that oxytocin, phosphodiesterase, neurokinin, and glycine play a crucial role in Schizophrenia." | 9.41 | Update on Oxytocin, Phosphodiesterase, Neurokinin, Glycine as a Therapeutic Approach in the Treatment of Schizophrenia. ( Bandiwadekar, T; Bhatia, N; Doshi, G; Godad, A; Kale, P; Kulkarni, D; Naik, J; Pandya, A; Ved, H, 2023) |
| "Currently, we observe a huge number of publications describing the role of glycine transporter (GlyT1) inhibitors in schizophrenia treatment." | 9.22 | Glycine transporters in schizophrenia. A new hope or informational noise? ( Pawlak, J; Zakowicz, P, 2022) |
| "Based on the hypothesis of NMDA receptor hypofunction in schizophrenia, plasma glycine, L-serine, and D-serine levels have been studied, since they could serve as biological markers." | 9.13 | Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). ( Abe, S; Arai, H; Hanzawa, R; Hatano, T; Kida, S; Maeshima, H; Ohnuma, T; Sakai, Y; Shibata, N; Suzuki, T, 2008) |
| "This study seeks to replicate previous results indicating that T102C in the serotonin 2A receptor (HTR2A) and Ser9Gly in the dopamine D3 receptor (DRD3) were associated with a risperidone response to acutely exacerbated schizophrenia, and to determine whether possession of these alleles predicts clinical improvement in a naturalistic setting." | 9.13 | Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. ( Choi, EY; Joo, YH; Kim, B; Kim, CY; Song, K, 2008) |
| "Clinical trials indicate that glycine site agonists of the N-methyl-D-aspartate (NMDA) receptors may reduce negative and cognitive symptoms in treatment-resistant schizophrenia when used as adjuvants to conventional antipsychotics but possibly not to clozapine." | 9.11 | High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. ( Bar, G; Ermilov, M; Heresco-Levy, U; Javitt, DC; Lichtenberg, P, 2004) |
| "We previously reported that plasma levels of glycine, a co-agonist at N-methyl-D-asparate (NMDA)-type glutamate receptors, are decreased in patients with schizophrenia, and that glycine levels are negatively correlated with negative symptoms." | 9.11 | Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. ( Jayathilake, K; Jin, D; Lee, M; Meltzer, HY; Sumiyoshi, T, 2005) |
| "The purpose of this study was to evaluate the effects of high-dose oral glycine on positive and negative symptoms and cognitive function when added to clozapine in adults with schizophrenia." | 9.09 | Placebo-controlled trial of glycine added to clozapine in schizophrenia. ( Evins, AE; Fitzgerald, SM; Goff, DC; Rosselli, R; Wine, L, 2000) |
| "Forty-seven patients with schizophrenia meeting criteria for deficit syndrome were randomized to D-cycloserine, 50 mg/d (n=23) or placebo (n=24) added to their conventional neuroleptic for an 8-week, double-blind trial." | 9.09 | A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. ( Amico, E; Coyle, JT; Goff, DC; Hayden, DL; Levitt, J; Manoach, D; McCarley, R; Schoenfeld, DA; Tsai, G, 1999) |
| "The focus of this study was the systematic evaluation of the clinical effects of glycine as an adjunct to the atypical antipsychotic clozapine in the treatment of schizophrenia." | 9.09 | Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. ( Bunney, BG; Costa, J; Gulasekaram, B; Jin, Y; Potkin, SG, 1999) |
| " In a double-blind, placebo-controlled fashion, 14 medicated patients with chronic schizophrenia were treated with glycine, a potentiator of NMDA-receptor-mediated neurotransmission." | 9.07 | Amelioration of negative symptoms in schizophrenia by glycine. ( Heresco-Levy, U; Javitt, DC; Lindenmayer, JP; Zukin, SR; Zylberman, I, 1994) |
| "Based upon the evidence that N-methyl-D-aspartate (NMDA) type glutamate receptor antagonists including phencyclidine cause schizophrenia-like treatment-resistant negative symptoms as well as antipsychotic-responsive dopamine-related positive symptoms, the facilitation of the NMDA receptor function has been considered to be a rational therapeutic approach to ameliorate both of the above schizophrenic symptomatologies." | 8.86 | [Development of a novel pharmacotherapy targeted at the N-methyl-D-aspartate receptor-D-serine system for schizophrenia]. ( Nishikawa, T, 2010) |
| "The present findings continue to support the use of N-methyl-D-aspartate/glycine site agonists as potential new treatments for persistent negative symptoms of schizophrenia." | 8.83 | Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. ( Javitt, DC, 2006) |
| "Since the hypofunction of the N-methyl-D-aspartate (NMDA) receptor is known to be involved in the pathophysiology of schizophrenia, the enhancement of NMDA receptor function through glycine modulatory sites is expected to be a useful approach for the treatment of schizophrenia." | 7.81 | Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia. ( Abe, K; Aoki, T; Chaki, S; Iijima, M; Kaku, A; Kambe, D; Karasawa, J; Kawakita, Y; Okubo, T; Okuyama, S; Sekiguchi, Y; Shibata, T; Shimazaki, T; Yamamoto, S, 2015) |
| "Behavioral phenotypes relevant to schizophrenia were assessed in Grin1(D481N) mice that have reduced NMDAR glycine affinity." | 7.74 | Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. ( Labrie, V; Lipina, T; Roder, JC, 2008) |
| "The NMDA receptor co-agonists D-serine and glycine are thought to contribute to glutamatergic dysfunction in schizophrenia." | 7.74 | Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia. ( Brandon, NJ; Burnet, PW; Gilbert, EJ; Harrison, PJ; Hutchinson, L; Hutson, PH; Rutter, AR; von Hesling, M, 2008) |
| "These findings support the hypothesis that altered levels of glycine and homocysteine may coexist in patients with schizophrenia and contribute to pathophysiological aspects of this illness." | 7.73 | Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. ( Blanaru, M; Bloch, B; Ermilov, M; Heresco-Levy, U; Javitt, DC; Kremer, I; Neeman, G, 2005) |
| "Serum levels of D-serine in the patients with schizophrenia were significantly (z = -3." | 7.72 | Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. ( Fukushima, T; Hasegawa, H; Hashimoto, K; Imai, K; Iyo, M; Komatsu, N; Kumakiri, C; Nakazato, M; Okada, S; Shimizu, E; Shinoda, N; Watanabe, H, 2003) |
| "Glycine treatment was associated with an 8-fold increase in serum glycine levels, similar to that observed previously." | 6.70 | Adjunctive high-dose glycine in the treatment of schizophrenia. ( Bark, N; Cienfuegos, A; Javitt, DC; Lindenmayer, JP; Park, M; Shelley, AM; Silipo, G; Suckow, R; Zukin, SR, 2001) |
| "Glycine treatment was well tolerated and induced increased glycine (P=." | 6.69 | Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. ( Ermilov, M; Heresco-Levy, U; Javitt, DC; Lichtenstein, M; Mordel, C; Silipo, G, 1999) |
| "Glycine was well tolerated, resulted in significantly increased serum glycine levels and induced a mean 36 (7%) reduction in negative symptoms (P < 0." | 6.68 | Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. ( Ermilov, M; Heresco-Levy, U; Horowitz, A; Javitt, DC; Kelly, D; Mordel, C, 1996) |
| "Schizophrenia is a severe psychiatric illness that is characterized by reduced cortical connectivity, for which the underlying biological and genetic causes are not well understood." | 6.52 | The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond. ( Balu, DT; Coyle, JT, 2015) |
| "A proposed approach to treatment of schizophrenia, therefore, is inhibition of GlyT1-mediated transport." | 6.48 | Glycine transport inhibitors in the treatment of schizophrenia. ( Javitt, DC, 2012) |
| "Schizophrenia is a severe neuropsychiatric disorder for which there is no adequate current treatment." | 6.45 | Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. ( Javitt, DC, 2009) |
| "These approaches may provide novel treatments to schizophrenia, provided that some of the known adverse effects associated with existing GlyT1 agents can be safely and adequately dealt with." | 6.44 | Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. ( Svensson, KA; Yang, CR, 2008) |
| "Pretreatment with glycine attenuated both, the ketamine-induced alterations of the aeGBR amplitude and the increased PANSS negative scores in glycine-responders, classified based on relative aeGBR increase." | 5.72 | Glycine attenuates impairments of stimulus-evoked gamma oscillations in the ketamine model of schizophrenia. ( Curic, S; Haaf, M; Leicht, G; Mulert, C; Rauh, J; Steinmann, S, 2022) |
| "Current literature supported by preclinical and clinical provides substantial evidence that oxytocin, phosphodiesterase, neurokinin, and glycine play a crucial role in Schizophrenia." | 5.41 | Update on Oxytocin, Phosphodiesterase, Neurokinin, Glycine as a Therapeutic Approach in the Treatment of Schizophrenia. ( Bandiwadekar, T; Bhatia, N; Doshi, G; Godad, A; Kale, P; Kulkarni, D; Naik, J; Pandya, A; Ved, H, 2023) |
| "Twenty-two patients with treatment-resistant schizophrenia and 22 age- and gender-matched healthy controls were enrolled." | 5.40 | Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment. ( Fujimoto, M; Fujita, Y; Hashimoto, K; Hashimoto, R; Ito, A; Numata, S; Ohi, K; Ohmori, T; Takeda, M; Umeda-Yano, S; Yamamori, H; Yasuda, Y, 2014) |
| "Glycine serum levels were measured by high performance liquid chromatography (HPLC)." | 5.36 | Glycine serum level in schizophrenia: relation to negative symptoms. ( Cermakova, E; Doubek, P; Hons, J; Libiger, J; Ulrychova, M; Zirko, R, 2010) |
| "Glycine (GLY), which acts as an obligatory co-agonist at the NMDAR-GLY site, induces PPI deficits in rats although, consistent with the hypo-NMDAR hypothesis, improves negative and cognitive symptoms in schizophrenia patients." | 5.34 | High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. ( Bar, G; Ebstein, RP; Ermilov, M; Heresco-Levy, U; Javitt, DC; Levin, R, 2007) |
| "Glycine was administered in an effort to facilitate endogenous glutamatergic transmission at the level of the N-methyl-D-aspartate (NMDA) receptor complex, since a glutamatergic deficiency in the pathophysiology of schizophrenia has been postulated." | 5.28 | Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. ( Banay-Schwartz, M; Cohen, CG; Deutsch, SI; Leighton, M; Rosse, RB; Scarcella, E; Theut, SK, 1989) |
| "BI 425809 is a potent and selective glycine transporter 1 (GlyT1) inhibitor being developed for the treatment of cognitive impairment in Alzheimer disease and schizophrenia." | 5.27 | Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies. ( Desch, M; Dorner-Ciossek, C; Fillon, G; Giovannini, R; Goetz, S; Keller, S; Kleiner, O; Liesenfeld, KH; Moschetti, V; Ramael, S; Rosenbrock, H; Schlecker, C; Schmid, B; Wind, S; Wunderlich, G, 2018) |
| "Currently, we observe a huge number of publications describing the role of glycine transporter (GlyT1) inhibitors in schizophrenia treatment." | 5.22 | Glycine transporters in schizophrenia. A new hope or informational noise? ( Pawlak, J; Zakowicz, P, 2022) |
| "To report the first three studies with SCH 900435, a selective glycine-1 re-uptake inhibitor in development for treating schizophrenia, using systematic evaluations of pharmacodynamics to understand the observed effects." | 5.17 | Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men. ( Cohen, AF; de Kam, ML; Franson, KL; Hogg, C; Holder, G; Kamerling, IM; Kleijn, HJ; Liem-Moolenaar, M; Peeters, P; Spaans, E; Udo De Haes, J; van Gerven, JM, 2013) |
| "This study seeks to replicate previous results indicating that T102C in the serotonin 2A receptor (HTR2A) and Ser9Gly in the dopamine D3 receptor (DRD3) were associated with a risperidone response to acutely exacerbated schizophrenia, and to determine whether possession of these alleles predicts clinical improvement in a naturalistic setting." | 5.13 | Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. ( Choi, EY; Joo, YH; Kim, B; Kim, CY; Song, K, 2008) |
| "N-Methyl D-aspartate (NMDA)-receptor hypofunction has been implicated in the pathophysiology of schizophrenia and D-serine and glycine add-on therapy to antipsychotics has shown beneficial effects in schizophrenic patients." | 5.13 | Cerebrospinal fluid D-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients. ( Berger, R; Cahn, W; De Barse, MM; de Koning, TJ; de Sain-van der Velden, MG; Dorland, L; Fuchs, SA; Kahn, RS; Klomp, LW; Scheepers, FE, 2008) |
| "Based on the hypothesis of NMDA receptor hypofunction in schizophrenia, plasma glycine, L-serine, and D-serine levels have been studied, since they could serve as biological markers." | 5.13 | Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). ( Abe, S; Arai, H; Hanzawa, R; Hatano, T; Kida, S; Maeshima, H; Ohnuma, T; Sakai, Y; Shibata, N; Suzuki, T, 2008) |
| "The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST) was a 16-week double-blind, double-dummy, parallel group, randomized clinical trial of adjunctive glycine, D-cycloserine, or placebo conducted at four sites in the United States and one site in Israel." | 5.12 | The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. ( Buchanan, RW; Carpenter, WT; Gold, JM; Heresco-Levy, U; Javitt, DC; Marder, SR; McMahon, RP; Schooler, NR, 2007) |
| "Clinical trials indicate that glycine site agonists of the N-methyl-D-aspartate (NMDA) receptors may reduce negative and cognitive symptoms in treatment-resistant schizophrenia when used as adjuvants to conventional antipsychotics but possibly not to clozapine." | 5.11 | High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. ( Bar, G; Ermilov, M; Heresco-Levy, U; Javitt, DC; Lichtenberg, P, 2004) |
| "We previously reported that plasma levels of glycine, a co-agonist at N-methyl-D-asparate (NMDA)-type glutamate receptors, are decreased in patients with schizophrenia, and that glycine levels are negatively correlated with negative symptoms." | 5.11 | Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. ( Jayathilake, K; Jin, D; Lee, M; Meltzer, HY; Sumiyoshi, T, 2005) |
| "Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia." | 5.11 | Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. ( Chang, WH; Chang, YC; Hsu, SK; Huang, CH; Lane, HY; Liu, YC, 2005) |
| "Forty-seven patients with schizophrenia meeting criteria for deficit syndrome were randomized to D-cycloserine, 50 mg/d (n=23) or placebo (n=24) added to their conventional neuroleptic for an 8-week, double-blind trial." | 5.09 | A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. ( Amico, E; Coyle, JT; Goff, DC; Hayden, DL; Levitt, J; Manoach, D; McCarley, R; Schoenfeld, DA; Tsai, G, 1999) |
| "The focus of this study was the systematic evaluation of the clinical effects of glycine as an adjunct to the atypical antipsychotic clozapine in the treatment of schizophrenia." | 5.09 | Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. ( Bunney, BG; Costa, J; Gulasekaram, B; Jin, Y; Potkin, SG, 1999) |
| "The purpose of this study was to evaluate the effects of high-dose oral glycine on positive and negative symptoms and cognitive function when added to clozapine in adults with schizophrenia." | 5.09 | Placebo-controlled trial of glycine added to clozapine in schizophrenia. ( Evins, AE; Fitzgerald, SM; Goff, DC; Rosselli, R; Wine, L, 2000) |
| " In a double-blind, placebo-controlled fashion, 14 medicated patients with chronic schizophrenia were treated with glycine, a potentiator of NMDA-receptor-mediated neurotransmission." | 5.07 | Amelioration of negative symptoms in schizophrenia by glycine. ( Heresco-Levy, U; Javitt, DC; Lindenmayer, JP; Zukin, SR; Zylberman, I, 1994) |
| "Over the last 20 years, glutamatergic models of schizophrenia have become increasingly accepted as etiopathological models of schizophrenia, based on the observation that phencyclidine (PCP) induces a schizophrenia-like psychosis by blocking neurotransmission at N-methyl-D-aspartate (NMDA)-type glutamate receptors." | 4.88 | Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. ( Heresco-Levy, U; Javitt, DC; Umbricht, D; Zukin, SR, 2012) |
| " As an example of a mechanistic biomarker, we described the work done to progress the novel class of glycine transporter inhibitors as putative treatment for negative symptoms of schizophrenia." | 4.88 | Biomarkers for antipsychotic therapies. ( Domenici, E; Pich, EM; Vargas, G, 2012) |
| "Taking into consideration the number of trials and sample size in subgroup analyses, D-serine, NAC and sarcosine as adjuncts to non-clozapine antipsychotics have therapeutic benefit in the treatment of negative and total symptoms of chronic schizophrenia." | 4.87 | Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. ( Singh, SP; Singh, V, 2011) |
| "Based upon the evidence that N-methyl-D-aspartate (NMDA) type glutamate receptor antagonists including phencyclidine cause schizophrenia-like treatment-resistant negative symptoms as well as antipsychotic-responsive dopamine-related positive symptoms, the facilitation of the NMDA receptor function has been considered to be a rational therapeutic approach to ameliorate both of the above schizophrenic symptomatologies." | 4.86 | [Development of a novel pharmacotherapy targeted at the N-methyl-D-aspartate receptor-D-serine system for schizophrenia]. ( Nishikawa, T, 2010) |
| "The present findings continue to support the use of N-methyl-D-aspartate/glycine site agonists as potential new treatments for persistent negative symptoms of schizophrenia." | 4.83 | Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. ( Javitt, DC, 2006) |
| "Polymorphisms in several genes known to interact with NMDA receptors are related to an altered risk for schizophrenia, and psychotic patients display changes in levels of mRNA encoding NMDA receptors, including the NR1 subunit on which Glycine(B) sites are located." | 4.82 | N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. ( Millan, MJ, 2005) |
| "N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP) and ketamine have been known to cause schizophrenia-like psychosis (positive symptoms, negative symptoms, cognitive dysfunction) in humans." | 4.81 | [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs]. ( Hashimoto, K; Iyo, M, 2002) |
| "Since the hypofunction of the N-methyl-D-aspartate (NMDA) receptor is known to be involved in the pathophysiology of schizophrenia, the enhancement of NMDA receptor function through glycine modulatory sites is expected to be a useful approach for the treatment of schizophrenia." | 3.81 | Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia. ( Abe, K; Aoki, T; Chaki, S; Iijima, M; Kaku, A; Kambe, D; Karasawa, J; Kawakita, Y; Okubo, T; Okuyama, S; Sekiguchi, Y; Shibata, T; Shimazaki, T; Yamamoto, S, 2015) |
| "Sarcosine is an amino acid involved in one-carbon metabolism and a promising therapy for schizophrenia because it enhances NMDA receptor (NMDAR) function by inhibiting glycine uptake." | 3.75 | The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine. ( Hyrc, K; Thio, LL; Zhang, HX, 2009) |
| "The NMDA receptor co-agonists D-serine and glycine are thought to contribute to glutamatergic dysfunction in schizophrenia." | 3.74 | Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia. ( Brandon, NJ; Burnet, PW; Gilbert, EJ; Harrison, PJ; Hutchinson, L; Hutson, PH; Rutter, AR; von Hesling, M, 2008) |
| "Behavioral phenotypes relevant to schizophrenia were assessed in Grin1(D481N) mice that have reduced NMDAR glycine affinity." | 3.74 | Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. ( Labrie, V; Lipina, T; Roder, JC, 2008) |
| "These findings support the hypothesis that altered levels of glycine and homocysteine may coexist in patients with schizophrenia and contribute to pathophysiological aspects of this illness." | 3.73 | Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. ( Blanaru, M; Bloch, B; Ermilov, M; Heresco-Levy, U; Javitt, DC; Kremer, I; Neeman, G, 2005) |
| "Augmentation strategy in the treatment of schizophrenia with the NMDA receptor co-agonist glycine has demonstrated significant improvement in patient symptoms." | 3.72 | Effects of typical and atypical antipsychotics on human glycine transporters. ( Conn, PJ; Mallorga, PJ; Pettibone, DJ; Sur, C; Williams, JB, 2004) |
| "Serum levels of D-serine in the patients with schizophrenia were significantly (z = -3." | 3.72 | Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. ( Fukushima, T; Hasegawa, H; Hashimoto, K; Imai, K; Iyo, M; Komatsu, N; Kumakiri, C; Nakazato, M; Okada, S; Shimizu, E; Shinoda, N; Watanabe, H, 2003) |
| "Elevation of glycine levels and activation of the NMDA receptor by inhibition of the glycine transporter 1 (GlyT-1) is a potential strategy for the treatment of schizophrenia." | 3.72 | The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors. ( Alifrangis, LH; Andersen, K; Brandt, G; Christoffersen, CT; Harris, N; Mikkelsen, G; Mørk, A; Ruhland, T; Smith, G; Wren, SP; Wyman, BM, 2004) |
| "Phencyclidine (PCP) and other N-methyl-D-aspartate (NMDA) antagonists induce schizophrenia-like symptoms in humans." | 3.70 | Inhibition of striatal dopamine release by glycine and glycyldodecylamide. ( Hashim, A; Javitt, DC; Lajtha, A; Sershen, H, 2000) |
| "Fasting plasma serine and glycine concentrations, determined by ion-exchange amino acid chromatography, were similar in a large group of psychotic patients with various forms of schizophrenia and in healthy control subjects." | 3.67 | Interconversion of serine and glycine is normal in psychotic patients. ( Hansen, S; Perry, TL, 1985) |
| "Aripiprazole has high affinity for dopamine D2 and D3 receptors (DRD2 and DRD3)." | 2.74 | Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. ( Chen, CH; Chen, SF; Shen, YC, 2009) |
| "Schizophrenia is commonly associated with impairments in pre-attentive change detection as represented by reduced mismatch negativity (MMN)." | 2.73 | Acute high-dose glycine attenuates mismatch negativity (MMN) in healthy human controls. ( Croft, RJ; Leung, S; Nathan, PJ; O'Neill, BV, 2008) |
| "Glycine treatment was associated with an 8-fold increase in serum glycine levels, similar to that observed previously." | 2.70 | Adjunctive high-dose glycine in the treatment of schizophrenia. ( Bark, N; Cienfuegos, A; Javitt, DC; Lindenmayer, JP; Park, M; Shelley, AM; Silipo, G; Suckow, R; Zukin, SR, 2001) |
| "Glycine treatment was well tolerated and induced increased glycine (P=." | 2.69 | Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. ( Ermilov, M; Heresco-Levy, U; Javitt, DC; Lichtenstein, M; Mordel, C; Silipo, G, 1999) |
| "D-cycloserine has been used for this purpose." | 2.69 | D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. ( Evenblij, CN; Kahn, RS; Maas, MF; van Berckel, BN; van der Geld, MA; van Loon, BJ; van Ree, JM; Wynne, HJ, 1999) |
| "Glycine was well tolerated, resulted in significantly increased serum glycine levels and induced a mean 36 (7%) reduction in negative symptoms (P < 0." | 2.68 | Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. ( Ermilov, M; Heresco-Levy, U; Horowitz, A; Javitt, DC; Kelly, D; Mordel, C, 1996) |
| "Schizophrenia is a severe psychiatric illness that is characterized by reduced cortical connectivity, for which the underlying biological and genetic causes are not well understood." | 2.52 | The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond. ( Balu, DT; Coyle, JT, 2015) |
| "Current treatments for schizophrenia, although effective for positive symptoms, have not proven as effective for negative symptoms and cognitive dysfunction." | 2.50 | Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. ( Citrome, L, 2014) |
| "A proposed approach to treatment of schizophrenia, therefore, is inhibition of GlyT1-mediated transport." | 2.48 | Glycine transport inhibitors in the treatment of schizophrenia. ( Javitt, DC, 2012) |
| "Schizophrenia is a severe neuropsychiatric disorder for which there is no adequate current treatment." | 2.45 | Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. ( Javitt, DC, 2009) |
| "These approaches may provide novel treatments to schizophrenia, provided that some of the known adverse effects associated with existing GlyT1 agents can be safely and adequately dealt with." | 2.44 | Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. ( Svensson, KA; Yang, CR, 2008) |
| " So far it is not clear whether NMDA receptor antagonists including glycine antagonists would be suitable for chronic administration because of their effects on cognition, learning and motor function." | 2.40 | The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications. ( Dannhardt, G; Kohl, BK, 1998) |
| "Pretreatment with glycine attenuated both, the ketamine-induced alterations of the aeGBR amplitude and the increased PANSS negative scores in glycine-responders, classified based on relative aeGBR increase." | 1.72 | Glycine attenuates impairments of stimulus-evoked gamma oscillations in the ketamine model of schizophrenia. ( Curic, S; Haaf, M; Leicht, G; Mulert, C; Rauh, J; Steinmann, S, 2022) |
| "Twenty-two patients with treatment-resistant schizophrenia and 22 age- and gender-matched healthy controls were enrolled." | 1.40 | Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment. ( Fujimoto, M; Fujita, Y; Hashimoto, K; Hashimoto, R; Ito, A; Numata, S; Ohi, K; Ohmori, T; Takeda, M; Umeda-Yano, S; Yamamori, H; Yasuda, Y, 2014) |
| "Schizophrenia is a heartbreaking, debilitating, youth-stealing, lifetime disorder for most individuals afflicted with it." | 1.38 | Biological perspectives: the role of glutamate in schizophrenia and its treatment. ( Grant, JS; Keltner, NL; Moore, RL; Steele, D; Swan, NA, 2012) |
| "Schizophrenia is a heritable, complex mental disorder." | 1.37 | Association study of DRD3 gene in schizophrenia in Mexican sib-pairs. ( Aguilar, A; Apiquián, R; Camarena, B; Carnevale, A; Fresán, A; Nicolini, H; Orozco, L; Urraca, N, 2011) |
| "Glycine serum levels were measured by high performance liquid chromatography (HPLC)." | 1.36 | Glycine serum level in schizophrenia: relation to negative symptoms. ( Cermakova, E; Doubek, P; Hons, J; Libiger, J; Ulrychova, M; Zirko, R, 2010) |
| "Schizophrenia is a life-long, severe, and disabling brain disorder that requires chronic pharmacotherapy." | 1.36 | The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex. ( Boules, M; Li, Z; Peris, J; Richelson, E; Williams, K, 2010) |
| "Schizophrenia is a serious mental disorder." | 1.35 | Complementary and alternative medicine in the treatment of schizophrenia. ( Babić, D; Babić, R, 2009) |
| "Glycine (GLY), which acts as an obligatory co-agonist at the NMDAR-GLY site, induces PPI deficits in rats although, consistent with the hypo-NMDAR hypothesis, improves negative and cognitive symptoms in schizophrenia patients." | 1.34 | High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. ( Bar, G; Ebstein, RP; Ermilov, M; Heresco-Levy, U; Javitt, DC; Levin, R, 2007) |
| "Schizophrenia is a major mental disorder." | 1.34 | Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine. ( Javitt, DC; Lifshitz, K; Linn, GS; O'Keeffe, RT; Schroeder, C, 2007) |
| "Using the rat Maximal Electroshock Seizure Threshold (MEST) test, (S)-3,4-DCPG (30 mg/kg, i." | 1.34 | Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia. ( Harris, AJ; Honey, A; Jones, DN; Jones, GA; Kelly, FM; Kew, JN; Maycox, PR; Melarange, RA; Murdock, PR; Robbins, MJ; Rocheville, M; Rourke, C; Rupniak, T; Soffin, EM; Starr, KR; Strum, J, 2007) |
| "Schizophrenia is a complex and severe disorder of unknown cause and pathophysiology." | 1.30 | Gly(247)-->Asp proenkephalin A mutation is rare in schizophrenia populations. ( Barron, YD; McMurray, CT; Mikesell, MJ; Nimgaonkar, VL; Sobell, JL; Sommer, SS, 1997) |
| "Glycine was administered in an effort to facilitate endogenous glutamatergic transmission at the level of the N-methyl-D-aspartate (NMDA) receptor complex, since a glutamatergic deficiency in the pathophysiology of schizophrenia has been postulated." | 1.28 | Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. ( Banay-Schwartz, M; Cohen, CG; Deutsch, SI; Leighton, M; Rosse, RB; Scarcella, E; Theut, SK, 1989) |
| "Glycine levels in RBC were also significantly higher in patients on Li+ compared to normals or Li+ free affective disorder patients." | 1.26 | Elevation of choline and glycine in red blood cells of psychiatric patients due to lithium treatment. ( Hendrie, HC; Shea, PA; Small, JG, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (8.06) | 18.7374 |
| 1990's | 40 (21.51) | 18.2507 |
| 2000's | 78 (41.94) | 29.6817 |
| 2010's | 47 (25.27) | 24.3611 |
| 2020's | 6 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Maksymetz, J | 1 |
| Byun, NE | 1 |
| Luessen, DJ | 1 |
| Li, B | 1 |
| Barry, RL | 1 |
| Gore, JC | 1 |
| Niswender, CM | 1 |
| Lindsley, CW | 2 |
| Joffe, ME | 1 |
| Conn, PJ | 2 |
| Haaf, M | 1 |
| Curic, S | 1 |
| Steinmann, S | 1 |
| Rauh, J | 1 |
| Leicht, G | 1 |
| Mulert, C | 1 |
| Doshi, G | 1 |
| Bhatia, N | 1 |
| Ved, H | 1 |
| Pandya, A | 1 |
| Kulkarni, D | 1 |
| Naik, J | 1 |
| Bandiwadekar, T | 1 |
| Godad, A | 1 |
| Kale, P | 1 |
| Zakowicz, P | 1 |
| Pawlak, J | 1 |
| Fone, KCF | 1 |
| Watson, DJG | 1 |
| Billiras, RI | 1 |
| Sicard, DI | 1 |
| Dekeyne, A | 1 |
| Rivet, JM | 1 |
| Gobert, A | 1 |
| Millan, MJ | 2 |
| Ostojic, SM | 1 |
| Greenwood, LM | 1 |
| Leung, S | 2 |
| Michie, PT | 1 |
| Green, A | 1 |
| Nathan, PJ | 2 |
| Fitzgerald, P | 1 |
| Johnston, P | 1 |
| Solowij, N | 1 |
| Kulkarni, J | 1 |
| Croft, RJ | 2 |
| Lee, M | 3 |
| Balla, A | 1 |
| Sershen, H | 3 |
| Sehatpour, P | 1 |
| Lakatos, P | 1 |
| Javitt, DC | 27 |
| Kim, SY | 1 |
| Kaufman, MJ | 1 |
| Cohen, BM | 1 |
| Jensen, JE | 1 |
| Coyle, JT | 7 |
| Du, F | 1 |
| Öngür, D | 1 |
| Panizzutti, R | 1 |
| Fisher, M | 1 |
| Garrett, C | 1 |
| Man, WH | 1 |
| Sena, W | 1 |
| Madeira, C | 1 |
| Vinogradov, S | 1 |
| Rosenbrock, H | 1 |
| Desch, M | 1 |
| Kleiner, O | 1 |
| Dorner-Ciossek, C | 1 |
| Schmid, B | 1 |
| Keller, S | 1 |
| Schlecker, C | 1 |
| Moschetti, V | 1 |
| Goetz, S | 1 |
| Liesenfeld, KH | 1 |
| Fillon, G | 1 |
| Giovannini, R | 1 |
| Ramael, S | 1 |
| Wunderlich, G | 1 |
| Wind, S | 1 |
| Li, YX | 1 |
| Yang, JY | 1 |
| Alcantara, M | 1 |
| Abelian, G | 1 |
| Kulkarni, A | 1 |
| Staubli, U | 1 |
| Foster, AC | 1 |
| Koshiyama, D | 1 |
| Kirihara, K | 1 |
| Tada, M | 1 |
| Nagai, T | 1 |
| Fujioka, M | 1 |
| Usui, K | 1 |
| Koike, S | 1 |
| Suga, M | 1 |
| Araki, T | 1 |
| Hashimoto, K | 7 |
| Kasai, K | 1 |
| Hayakawa, E | 1 |
| Ohgidani, M | 1 |
| Fujimura, Y | 1 |
| Kanba, S | 1 |
| Miura, D | 1 |
| Kato, TA | 1 |
| Heresco-Levy, U | 13 |
| Shoham, S | 2 |
| Chue, PS | 1 |
| Baker, GB | 2 |
| Harvey, RJ | 1 |
| Yee, BK | 3 |
| Citrome, L | 1 |
| Dolgin, E | 1 |
| Hoffman, KL | 2 |
| Basurto, E | 2 |
| Yamamori, H | 1 |
| Hashimoto, R | 1 |
| Fujita, Y | 1 |
| Numata, S | 1 |
| Yasuda, Y | 1 |
| Fujimoto, M | 1 |
| Ohi, K | 1 |
| Umeda-Yano, S | 1 |
| Ito, A | 1 |
| Ohmori, T | 1 |
| Takeda, M | 1 |
| Kawaura, K | 1 |
| Koike, H | 1 |
| Kinoshita, K | 1 |
| Kambe, D | 2 |
| Kaku, A | 2 |
| Karasawa, J | 2 |
| Chaki, S | 2 |
| Hikichi, H | 1 |
| Balu, DT | 2 |
| Flores, OG | 1 |
| Shimazaki, T | 1 |
| Aoki, T | 1 |
| Iijima, M | 1 |
| Yamamoto, S | 1 |
| Kawakita, Y | 1 |
| Shibata, T | 1 |
| Abe, K | 1 |
| Okubo, T | 1 |
| Sekiguchi, Y | 1 |
| Okuyama, S | 1 |
| Möller, HJ | 2 |
| Czobor, P | 1 |
| Singer, P | 2 |
| Dubroqua, S | 1 |
| Engel, JA | 1 |
| Jerlhag, E | 1 |
| Svensson, L | 1 |
| Smith, RG | 1 |
| Egecioglu, E | 1 |
| Hofmann, C | 1 |
| Pizzagalli, F | 1 |
| Boetsch, C | 1 |
| Alberati, D | 1 |
| Ereshefsky, L | 1 |
| Jhee, S | 1 |
| Patat, A | 1 |
| Boutouyrie-Dumont, B | 1 |
| Martin-Facklam, M | 1 |
| Nishikawa, T | 3 |
| Labrie, V | 3 |
| Lipina, T | 1 |
| Roder, JC | 3 |
| Boulay, D | 1 |
| Pichat, P | 1 |
| Dargazanli, G | 1 |
| Estenne-Bouhtou, G | 1 |
| Terranova, JP | 1 |
| Rogacki, N | 1 |
| Stemmelin, J | 1 |
| Coste, A | 1 |
| Lanneau, C | 1 |
| Desvignes, C | 1 |
| Cohen, C | 1 |
| Alonso, R | 1 |
| Vigé, X | 1 |
| Biton, B | 1 |
| Steinberg, R | 1 |
| Sevrin, M | 1 |
| Oury-Donat, F | 1 |
| George, P | 1 |
| Bergis, O | 1 |
| Griebel, G | 1 |
| Avenet, P | 1 |
| Scatton, B | 1 |
| Barak, S | 1 |
| Weiner, I | 1 |
| Yang, CR | 1 |
| Svensson, KA | 1 |
| Ohnuma, T | 3 |
| Sakai, Y | 2 |
| Maeshima, H | 3 |
| Hatano, T | 2 |
| Hanzawa, R | 3 |
| Abe, S | 1 |
| Kida, S | 1 |
| Shibata, N | 3 |
| Suzuki, T | 1 |
| Arai, H | 3 |
| Rizos, EN | 1 |
| Siafakas, N | 1 |
| Katsantoni, E | 1 |
| Lazou, V | 1 |
| Sakellaropoulos, K | 1 |
| Kastania, A | 1 |
| Kossida, S | 1 |
| Chatzigeorgiou, KS | 1 |
| Arsenis, G | 1 |
| Zerva, L | 1 |
| Katsafouros, K | 1 |
| Lykouras, L | 1 |
| Zai, CC | 2 |
| Tiwari, AK | 1 |
| De Luca, V | 2 |
| Müller, DJ | 1 |
| Bulgin, N | 2 |
| Hwang, R | 1 |
| Zai, GC | 1 |
| King, N | 1 |
| Voineskos, AN | 1 |
| Meltzer, HY | 4 |
| Lieberman, JA | 3 |
| Potkin, SG | 3 |
| Remington, G | 2 |
| Kennedy, JL | 3 |
| Baba, H | 1 |
| Chen, SF | 1 |
| Shen, YC | 1 |
| Chen, CH | 2 |
| Powell, SB | 1 |
| Zhou, X | 1 |
| Geyer, MA | 1 |
| Zhang, HX | 1 |
| Hyrc, K | 1 |
| Thio, LL | 1 |
| Al Hadithy, AF | 1 |
| Ivanova, SA | 1 |
| Pechlivanoglou, P | 1 |
| Semke, A | 1 |
| Fedorenko, O | 1 |
| Kornetova, E | 1 |
| Ryadovaya, L | 1 |
| Brouwers, JR | 1 |
| Wilffert, B | 1 |
| Bruggeman, R | 1 |
| Loonen, AJ | 1 |
| Wang, W | 1 |
| Barger, SW | 1 |
| Babić, D | 1 |
| Babić, R | 1 |
| Tsai, GE | 2 |
| Lin, PY | 1 |
| Li, Z | 2 |
| Boules, M | 1 |
| Williams, K | 1 |
| Peris, J | 1 |
| Richelson, E | 1 |
| Hons, J | 2 |
| Zirko, R | 1 |
| Ulrychova, M | 1 |
| Cermakova, E | 2 |
| Doubek, P | 2 |
| Libiger, J | 2 |
| Godlewska, BR | 1 |
| Olajossy-Hilkesberger, L | 1 |
| Limon, J | 1 |
| Landowski, J | 1 |
| Bitanihirwe, BK | 1 |
| Peleg-Raibstein, D | 1 |
| Mouttet, F | 1 |
| Feldon, J | 2 |
| Meyer, U | 1 |
| Nakato, K | 1 |
| Harada, K | 1 |
| Tobe, T | 1 |
| Yamaji, T | 1 |
| Takakura, S | 1 |
| Yoshikawa, T | 1 |
| Maekawa, M | 1 |
| Ohnishi, T | 1 |
| Watanabe, A | 2 |
| Urraca, N | 1 |
| Camarena, B | 1 |
| Aguilar, A | 1 |
| Fresán, A | 1 |
| Apiquián, R | 1 |
| Orozco, L | 1 |
| Carnevale, A | 1 |
| Nicolini, H | 1 |
| Singh, SP | 1 |
| Singh, V | 1 |
| Basu, AC | 1 |
| Corradi, JP | 1 |
| Cacace, AM | 1 |
| Vasatova, M | 1 |
| Steele, D | 1 |
| Moore, RL | 1 |
| Swan, NA | 1 |
| Grant, JS | 1 |
| Keltner, NL | 1 |
| Zukin, SR | 5 |
| Umbricht, D | 1 |
| Liem-Moolenaar, M | 1 |
| Peeters, P | 1 |
| Kamerling, IM | 1 |
| Hogg, C | 1 |
| Holder, G | 1 |
| Kleijn, HJ | 1 |
| Spaans, E | 1 |
| Udo De Haes, J | 1 |
| de Kam, ML | 1 |
| Franson, KL | 1 |
| Cohen, AF | 1 |
| van Gerven, JM | 1 |
| Pich, EM | 1 |
| Vargas, G | 1 |
| Domenici, E | 1 |
| Lutgen, V | 1 |
| Qualmann, K | 1 |
| Resch, J | 1 |
| Kong, L | 1 |
| Choi, S | 1 |
| Baker, DA | 2 |
| Chue, P | 1 |
| Higa, M | 1 |
| Kitazawa, M | 1 |
| Hotta, Y | 1 |
| Katsuta, N | 1 |
| Takebayashi, Y | 1 |
| Ventriglia, M | 1 |
| Bocchio Chiavetto, L | 1 |
| Bonvicini, C | 1 |
| Tura, GB | 1 |
| Bignotti, S | 1 |
| Racagni, G | 1 |
| Gennarelli, M | 1 |
| Jönsson, EG | 1 |
| Flyckt, L | 1 |
| Burgert, E | 1 |
| Crocq, MA | 1 |
| Forslund, K | 1 |
| Mattila-Evenden, M | 1 |
| Rylander, G | 1 |
| Asberg, M | 1 |
| Nimgaonkar, VL | 2 |
| Edman, G | 1 |
| Bjerkenstedt, L | 1 |
| Wiesel, FA | 1 |
| Sedvall, GC | 1 |
| Zhang, Z | 1 |
| Hou, G | 1 |
| Zhang, X | 2 |
| Yao, H | 1 |
| Sha, W | 1 |
| Fukushima, T | 1 |
| Shimizu, E | 1 |
| Komatsu, N | 1 |
| Watanabe, H | 1 |
| Shinoda, N | 1 |
| Nakazato, M | 1 |
| Kumakiri, C | 1 |
| Okada, S | 1 |
| Hasegawa, H | 1 |
| Imai, K | 1 |
| Iyo, M | 2 |
| MALL, G | 1 |
| JUNEMANN, HJ | 1 |
| LABROSSE, EH | 1 |
| KOPIN, IJ | 1 |
| FELIX, WR | 1 |
| WESTLAKE, RJ | 1 |
| PARK, LC | 1 |
| BALDESSARINI, RJ | 1 |
| KETY, SS | 1 |
| Tunbridge, E | 1 |
| Burnet, PW | 2 |
| Sodhi, MS | 1 |
| Harrison, PJ | 2 |
| Sumiyoshi, T | 2 |
| Anil, AE | 1 |
| Jin, D | 2 |
| Jayathilake, K | 2 |
| Bonta, IL | 1 |
| Luo, X | 1 |
| Klempan, TA | 1 |
| Lappalainen, J | 1 |
| Rosenheck, RA | 1 |
| Charney, DS | 1 |
| Erdos, J | 1 |
| van Kammen, DP | 1 |
| Kranzler, HR | 1 |
| Gelernter, J | 1 |
| Ermilov, M | 5 |
| Lichtenberg, P | 1 |
| Bar, G | 2 |
| Williams, NM | 1 |
| Preece, A | 1 |
| Spurlock, G | 2 |
| Norton, N | 1 |
| Williams, HJ | 1 |
| McCreadie, RG | 1 |
| Buckland, P | 1 |
| Sharkey, V | 1 |
| Chowdari, KV | 1 |
| Zammit, S | 1 |
| Nimgaonkar, V | 1 |
| Kirov, G | 1 |
| Owen, MJ | 2 |
| O'Donovan, MC | 1 |
| Tsai, G | 3 |
| Smith, G | 1 |
| Ruhland, T | 1 |
| Mikkelsen, G | 1 |
| Andersen, K | 1 |
| Christoffersen, CT | 1 |
| Alifrangis, LH | 1 |
| Mørk, A | 1 |
| Wren, SP | 1 |
| Harris, N | 1 |
| Wyman, BM | 1 |
| Brandt, G | 1 |
| Williams, JB | 1 |
| Mallorga, PJ | 1 |
| Pettibone, DJ | 1 |
| Sur, C | 2 |
| Duncan, EJ | 1 |
| Szilagyi, S | 1 |
| Schwartz, MP | 1 |
| Bugarski-Kirola, D | 1 |
| Kunzova, A | 1 |
| Negi, S | 1 |
| Stephanides, M | 1 |
| Efferen, TR | 1 |
| Angrist, B | 1 |
| Peselow, E | 1 |
| Corwin, J | 1 |
| Gonzenbach, S | 1 |
| Rotrosen, JP | 1 |
| Tuominen, HJ | 1 |
| Tiihonen, J | 1 |
| Wahlbeck, K | 1 |
| Lane, HY | 1 |
| Hsu, SK | 1 |
| Liu, YC | 1 |
| Chang, YC | 1 |
| Huang, CH | 1 |
| Chang, WH | 1 |
| Hashim, A | 2 |
| Diaz, P | 1 |
| Bhaskara, S | 1 |
| Dursun, SM | 1 |
| Deakin, B | 1 |
| Kéri, S | 1 |
| Juhász, A | 1 |
| Rimanóczy, A | 1 |
| Szekeres, G | 1 |
| Kelemen, O | 1 |
| Cimmer, C | 1 |
| Szendi, I | 1 |
| Benedek, G | 1 |
| Janka, Z | 1 |
| Gourion, D | 1 |
| Goldberger, C | 1 |
| Leroy, S | 1 |
| Bourdel, MC | 1 |
| Olié, JP | 1 |
| Krebs, MO | 1 |
| Neeman, G | 1 |
| Blanaru, M | 1 |
| Bloch, B | 1 |
| Kremer, I | 1 |
| Bly, M | 1 |
| Lechner, SM | 1 |
| Balic, E | 1 |
| Schwerdel, C | 1 |
| Grampp, T | 1 |
| Gabernet, L | 1 |
| Knuesel, I | 1 |
| Benke, D | 1 |
| Mohler, H | 1 |
| Boison, D | 1 |
| Harsing, LG | 1 |
| Juranyi, Z | 1 |
| Gacsalyi, I | 1 |
| Tapolcsanyi, P | 1 |
| Czompa, A | 1 |
| Matyus, P | 1 |
| Pietraszek, M | 1 |
| Nagel, J | 1 |
| Gravius, A | 1 |
| Schäfer, D | 1 |
| Danysz, W | 1 |
| Shipe, WD | 1 |
| Wolkenberg, SE | 1 |
| Theberge, CR | 1 |
| Williams, DL | 1 |
| Kinney, GG | 1 |
| Yamaguchi, K | 1 |
| Nakatani, A | 1 |
| Murasawa, H | 1 |
| Fujimura, K | 1 |
| Tatsumi, Y | 1 |
| Tatsumi, M | 1 |
| Schosser, A | 1 |
| Aschauer, HN | 2 |
| Wildenauer, DB | 1 |
| Schwab, SG | 1 |
| Albus, M | 2 |
| Maier, W | 2 |
| Schloegelhofer, M | 1 |
| Leisch, F | 1 |
| Hornik, K | 1 |
| Murray, SS | 1 |
| Gasche, C | 1 |
| Lorenzo, CV | 1 |
| Baca-Garcia, E | 1 |
| Hernandez, MD | 1 |
| Martin, CB | 1 |
| Perez-Rodriguez, MM | 1 |
| Saiz-Gonzalez, MD | 1 |
| Fernández, P | 1 |
| Gutierrez, FJ | 1 |
| Saiz-Ruiz, J | 1 |
| Piqueras, JF | 1 |
| de Rivera, JL | 1 |
| de Leon, J | 1 |
| Levin, R | 1 |
| Ebstein, RP | 1 |
| Mouri, A | 1 |
| Noda, Y | 1 |
| Noda, A | 1 |
| Nakamura, T | 1 |
| Tokura, T | 1 |
| Yura, Y | 1 |
| Nitta, A | 1 |
| Furukawa, H | 1 |
| Nabeshima, T | 1 |
| Linn, GS | 1 |
| O'Keeffe, RT | 1 |
| Lifshitz, K | 1 |
| Schroeder, C | 1 |
| Robbins, MJ | 1 |
| Starr, KR | 1 |
| Honey, A | 1 |
| Soffin, EM | 1 |
| Rourke, C | 1 |
| Jones, GA | 1 |
| Kelly, FM | 1 |
| Strum, J | 1 |
| Melarange, RA | 1 |
| Harris, AJ | 1 |
| Rocheville, M | 1 |
| Rupniak, T | 1 |
| Murdock, PR | 1 |
| Jones, DN | 1 |
| Kew, JN | 1 |
| Maycox, PR | 1 |
| Stahl, SM | 1 |
| Fathalli, F | 1 |
| Rouleau, GA | 1 |
| Xiong, L | 1 |
| Tabbane, K | 1 |
| Benkelfat, C | 1 |
| Deguzman, R | 1 |
| Zoltan, D | 1 |
| Lal, S | 1 |
| D'cruz, S | 1 |
| Joober, R | 1 |
| Madayag, A | 1 |
| Kristiansen, LV | 1 |
| Meador-Woodruff, JH | 1 |
| Haroutunian, V | 1 |
| Raju, I | 1 |
| Donohoe, G | 1 |
| Morris, DW | 1 |
| Robertson, IH | 1 |
| McGhee, KA | 1 |
| Murphy, K | 1 |
| Kenny, N | 1 |
| Clarke, S | 1 |
| Gill, M | 2 |
| Corvin, AP | 1 |
| Buchanan, RW | 2 |
| Marder, SR | 1 |
| Schooler, NR | 1 |
| Gold, JM | 1 |
| McMahon, RP | 1 |
| Carpenter, WT | 2 |
| Shim, SS | 1 |
| Hammonds, MD | 1 |
| Kee, BS | 1 |
| Kim, B | 1 |
| Choi, EY | 1 |
| Kim, CY | 1 |
| Song, K | 1 |
| Joo, YH | 1 |
| O'Neill, BV | 1 |
| Renou, J | 1 |
| Le Foll, B | 1 |
| Fuchs, SA | 1 |
| De Barse, MM | 1 |
| Scheepers, FE | 1 |
| Cahn, W | 1 |
| Dorland, L | 1 |
| de Sain-van der Velden, MG | 1 |
| Klomp, LW | 1 |
| Berger, R | 1 |
| Kahn, RS | 2 |
| de Koning, TJ | 1 |
| Ma, G | 1 |
| He, Z | 1 |
| Fang, W | 1 |
| Tang, W | 1 |
| Huang, K | 1 |
| He, G | 1 |
| Xu, Y | 1 |
| Feng, G | 1 |
| Zheng, T | 1 |
| Zhou, J | 1 |
| He, L | 1 |
| Shi, Y | 1 |
| Hutchinson, L | 1 |
| von Hesling, M | 1 |
| Gilbert, EJ | 1 |
| Brandon, NJ | 1 |
| Rutter, AR | 1 |
| Hutson, PH | 1 |
| Barlas, IO | 1 |
| Cetin, M | 1 |
| Erdal, ME | 1 |
| Semiz, UB | 1 |
| Basoglu, C | 1 |
| Ay, ME | 1 |
| Herken, H | 1 |
| Uzun, O | 1 |
| Takahashi, T | 1 |
| Suzuki, M | 1 |
| Tsunoda, M | 1 |
| Kawamura, Y | 1 |
| Takahashi, N | 1 |
| Maeno, N | 1 |
| Kawasaki, Y | 1 |
| Zhou, SY | 1 |
| Hagino, H | 1 |
| Niu, L | 1 |
| Tsuneki, H | 1 |
| Kobayashi, S | 1 |
| Sasaoka, T | 1 |
| Seto, H | 1 |
| Kurachi, M | 1 |
| Ozaki, N | 1 |
| Pepplinkhuizen, L | 2 |
| Bruinvels, J | 2 |
| Blom, W | 1 |
| Moleman, P | 1 |
| Deutsch, SI | 3 |
| Stanley, M | 1 |
| Peselow, ED | 1 |
| Banay-Schwartz, M | 2 |
| Shea, PA | 1 |
| Small, JG | 1 |
| Hendrie, HC | 1 |
| Zylberman, I | 3 |
| Seeman, P | 1 |
| Ulpian, C | 1 |
| Chouinard, G | 1 |
| Van Tol, HH | 1 |
| Dwosh, H | 1 |
| Siminovitch, K | 1 |
| Liu, IS | 1 |
| Waye, J | 1 |
| Voruganti, P | 1 |
| Baruah, S | 5 |
| Waziri, R | 8 |
| Sherman, A | 1 |
| Ishimaru, M | 2 |
| Kurumaji, A | 3 |
| Toru, M | 3 |
| Lindenmayer, JP | 2 |
| Lucca, A | 1 |
| Cortinovis, S | 1 |
| Lucini, V | 1 |
| Devor, EJ | 1 |
| Sherman, AD | 2 |
| Banerjee, SP | 1 |
| Zuck, LG | 1 |
| Yablonsky-Alter, E | 1 |
| Lidsky, TI | 1 |
| Rietschel, M | 1 |
| Nöthen, MM | 1 |
| Minges, J | 1 |
| Bondy, B | 1 |
| Körner, J | 1 |
| Hemmer, S | 1 |
| Fimmers, R | 1 |
| Wildenauer, D | 1 |
| Propping, P | 1 |
| Leiderman, E | 1 |
| Cooper, TB | 1 |
| Kumashiro, S | 1 |
| Semba, J | 2 |
| Mordel, C | 2 |
| Horowitz, A | 1 |
| Kelly, D | 1 |
| Silipo, G | 3 |
| Liu, MY | 1 |
| Wei, FC | 1 |
| Koong, FJ | 1 |
| Hwu, HG | 1 |
| Hsiao, KJ | 1 |
| Frusciante, M | 1 |
| Mikesell, MJ | 1 |
| Barron, YD | 1 |
| Sobell, JL | 1 |
| Sommer, SS | 1 |
| McMurray, CT | 1 |
| Malhotra, AK | 1 |
| Goldman, D | 1 |
| Rooney, W | 1 |
| Clifton, A | 1 |
| Kosmidis, MH | 1 |
| Breier, A | 1 |
| Pickar, D | 1 |
| Williams, J | 1 |
| McGuffin, P | 1 |
| Lenzinger, E | 1 |
| Fuchs, K | 1 |
| Sieghart, WC | 1 |
| Meszaros, K | 1 |
| Fathi, N | 1 |
| Laurent, C | 1 |
| Mallet, J | 1 |
| Macciardi, F | 1 |
| Pedrini, S | 1 |
| Hawi, Z | 1 |
| Gibson, S | 1 |
| Jazin, EE | 1 |
| Yang, HT | 1 |
| Adolfsson, R | 1 |
| Pato, CN | 1 |
| Dourado, AM | 1 |
| Dannhardt, G | 1 |
| Kohl, BK | 1 |
| Krystal, JH | 1 |
| D'Souza, DC | 1 |
| Farber, NB | 1 |
| Newcomer, JW | 1 |
| Olney, JW | 1 |
| Goff, DC | 3 |
| Levitt, J | 1 |
| Amico, E | 1 |
| Manoach, D | 1 |
| Schoenfeld, DA | 1 |
| Hayden, DL | 1 |
| McCarley, R | 1 |
| Lichtenstein, M | 1 |
| Jin, Y | 1 |
| Bunney, BG | 1 |
| Costa, J | 2 |
| Gulasekaram, B | 1 |
| Segman, R | 1 |
| Neeman, T | 1 |
| Finkel, B | 1 |
| Karagichev, L | 1 |
| Schlafman, M | 1 |
| Dorevitch, A | 1 |
| Yakir, A | 1 |
| Lerner, A | 1 |
| Shelevoy, A | 1 |
| Lerer, B | 1 |
| van Berckel, BN | 1 |
| Evenblij, CN | 1 |
| van Loon, BJ | 1 |
| Maas, MF | 1 |
| van der Geld, MA | 1 |
| Wynne, HJ | 1 |
| van Ree, JM | 1 |
| Yang, P | 1 |
| Chung, LC | 1 |
| Tsai, IC | 1 |
| Tsai, CW | 1 |
| Evins, AE | 1 |
| Fitzgerald, SM | 1 |
| Wine, L | 1 |
| Rosselli, R | 1 |
| Lajtha, A | 1 |
| Yamamoto, N | 1 |
| Tsuchida, H | 1 |
| Umino, A | 1 |
| Kawaguchi, N | 1 |
| Kato, K | 1 |
| Shishido, T | 1 |
| Ono, M | 1 |
| Shishido, K | 1 |
| Kobayashi, M | 1 |
| Niwa, S | 1 |
| Cordeiro, Q | 1 |
| Junqueira, R | 1 |
| Vallada, H | 1 |
| Cienfuegos, A | 1 |
| Shelley, AM | 1 |
| Bark, N | 1 |
| Park, M | 1 |
| Suckow, R | 1 |
| Kretschmer, BD | 1 |
| Schmidt, WJ | 1 |
| Hegwood, TS | 2 |
| Mallis, LM | 1 |
| Khaled, E | 1 |
| Sramek, J | 1 |
| Bunney, W | 1 |
| Mastropaolo, J | 1 |
| Schwartz, BL | 1 |
| Rosse, RB | 2 |
| Morihisa, JM | 1 |
| Theut, SK | 1 |
| Leighton, M | 1 |
| Scarcella, E | 1 |
| Cohen, CG | 1 |
| Korpi, ER | 1 |
| Kaufmann, CA | 1 |
| Marnela, KM | 1 |
| Weinberger, DR | 1 |
| Fekkes, D | 1 |
| Perry, TL | 1 |
| Hansen, S | 1 |
| Iversen, LL | 1 |
| Lovett Doust, JW | 1 |
| Huszka, L | 1 |
| Antun, FT | 1 |
| Burnett, GB | 1 |
| Cooper, AJ | 1 |
| Daly, RJ | 1 |
| Smythies, JR | 1 |
| Zealley, AK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia: A Randomised Placebo-controlled Double-blind Trial[NCT02533232] | Phase 1 | 60 participants (Anticipated) | Interventional | 2022-08-30 | Recruiting | ||
| Pilot Study of Glycine Augmentation in Carriers of a Mutation in the Gene Encoding Glycine Decarboxylase[NCT01720316] | Phase 2 | 2 participants (Actual) | Interventional | 2012-12-10 | Completed | ||
| Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine[NCT02304432] | Early Phase 1 | 2 participants (Actual) | Interventional | 2015-09-27 | Completed | ||
| Predictive Coding Abnormalities in Psychosis: EEG and fMRI[NCT03068806] | 202 participants (Actual) | Observational | 2014-12-01 | Completed | |||
| The Effects of Glycine Transport Inhibition on Brain Glycine Concentration[NCT00538070] | 68 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST)[NCT00222235] | Phase 2/Phase 3 | 240 participants | Interventional | 2000-01-31 | Completed | ||
| Acute Glycine Pharmacodynamic Study[NCT01610011] | 21 participants (Actual) | Interventional | 2010-07-31 | Completed | |||
| A Trial of the Effects of Glycine Loading on Clinical Symptoms and Logical Memory in Patients With Schizophrenia[NCT00575848] | Phase 1 | 16 participants (Anticipated) | Interventional | 2007-12-31 | Terminated (stopped due to Slow enrollment and due to personnel change there was no viable way to quantify glycine levels through imaging) | ||
| Controlled and Randomized Clinical Trial for Evaluating the Effect of a Supplement of Glycine as Adjuvant in the Treatment of COVID-19 Pneumonia in Patients Initiating Mechanical Ventilation[NCT04443673] | 59 participants (Actual) | Interventional | 2020-06-15 | Terminated (stopped due to An interim analysis showed no difference in major outcomes (n=35 glycine and n=24 control participants)) | |||
| The Effects of Glycine on Atherosclerosis and Metabolic Syndrome-related Parameters: A Clinical and Ex-vivo Study.[NCT03850314] | Phase 2/Phase 3 | 50 participants (Anticipated) | Interventional | 2019-03-31 | Not yet recruiting | ||
| D-Serine Augmentation of Cognitive Retraining in Schizophrenia[NCT00237848] | Phase 3 | 72 participants (Anticipated) | Interventional | 2005-02-28 | Completed | ||
| D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia[NCT00237809] | Phase 3 | 104 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Effect of Sarcosine on Symptomatology, Quality of Life, Cognitive and Sexual Functioning, Blood Levels of Sarcosine, Glycine, BDNF and MMP-9, Oculomotor, Brain Metabolism and Oxidative Stress Parameters in Schizophrenia.[NCT01503359] | Phase 2 | 70 participants (Anticipated) | Interventional | 2012-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Auditory evoked potentials amplitude: P50 ratio (S2/S1). Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | ratio (Number) |
|---|---|
| Auditory ERPs Amplitude (Deg) Baseline: Subject 2 | 44.51 |
| Auditory ERPs Amplitude (Deg) 6 Weeks of Glycine: Subject 2 | 35.67 |
Auditory evoked potentials amplitude: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz; P50 S1 and S2 amplitude; mismatch negativity (MMN) at fz and cz. Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | microvolts (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 amplitude at fz | P300 amplitude at cz | P300 amplitude at pz | N100 amplitude at fz | N100 amplitude at cz | P200 amplitude at fz | P200 amplitude at cz | P50 S1 amplitude | P50 S2 amplitude | MMN amplitude at fz | MMN amplitude at cz | |
| Auditory ERPs Amplitude (Deg) 6 Weeks of Glycine: Subject 2 | 3.74 | 6.6 | 5.57 | -4.71 | -3.89 | 6.29 | 7.8 | 2.2 | 0.78 | -1.004 | -1.322 |
| Auditory ERPs Amplitude (Deg) Baseline: Subject 2 | -0.635 | 6.53 | 5.34 | -3.93 | -3.62 | 1.662 | 6.59 | 2.76 | 1.23 | -3.356 | -4.13 |
Auditory evoked potentials gamma: G40 hz phase locking at fz and cz; G20 hz phase locking response at fz and cz G30 hz phase locking response at fz and cz. Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | microvolts squared (Number) | |||||
|---|---|---|---|---|---|---|
| G40 fz | G40 cz | G20 fz | G20 cz | G30 fz | G30 cz | |
| Auditory ERPs Gamma 6 Weeks of Glycine: Subject 2 | 0.255 | 0.29 | 0.107 | 0.108 | 0.177 | 0.242 |
| Auditory ERPs Gamma Baseline: Subject 2 | 0.135 | 0.168 | 0.023 | 0.03 | 0.19 | 0.163 |
Auditory evoked potentials latency: P300 at fz, cz, and pz); N100 at fz and cz); P200 at fz and cz. Participants were assessed at baseline and in week of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | msec (Number) | ||||||
|---|---|---|---|---|---|---|---|
| P300 latency at fz | P300 latency at cz | P300 latency at pz | N100 latency at fz | N100 latency at cz | P200 latency at fz | P200 latency at cz | |
| Auditory ERPs Latency (ms) 6 Weeks of Glycine: Subject 2 | 300.78 | 293 | 294.92 | 94 | 94 | 205 | 203 |
| Auditory ERPs Latency (ms) Baseline: Subject 2 | 279.3 | 279.3 | 279.3 | 97.66 | 91.8 | 197.27 | 193.4 |
Magnetic resonance spectroscopy GABA/Cr. Participants were assessed 1) pre-glycine treatment (baseline) and 2) in week 6 of open-label glycine treatment measured in posterior occipital cortex. (NCT01720316)
Timeframe: Baseline and week 6 of glycine
| Intervention | ratio (Number) | |
|---|---|---|
| Baseline GABA/Cr | Week 6 of glycine tx GABA/Cr | |
| Subject1: Brain GABA/CR Ratio- Baseline/Week 6 of Glycine | 0.16 | 0.22 |
| Subject2: Brain GABA/CR Ratio- Baseline/Week 6 of Glycine | 0.27 | 0.24 |
magnetic resonance spectroscopy - glutamate metabolite level. Participants were assessed 1) pre-glycine treatment and in week 6 of open-label glycine treatment. Measured in posterior occipital cortex. (NCT01720316)
Timeframe: baseline and week 6 of glycine
| Intervention | ratio (Number) | |
|---|---|---|
| Baseline brain glutamate/Cr ratio | Week 6 brain glutamate/Cr ratio | |
| Subject1: Brain Glutamate/CR Ratio- Baseline/Week 6 of Glycine | 0.98 | 0.84 |
| Subject2: Brain Glutamate/CR Ratio- Baseline/Week 6 of Glycine | 2.053 | 1.13 |
magnetic resonance spectroscopy: glycine/creatine ratio. Participants were assessed at 1) BASELINE PRE-GLYCINE TREATMENT: pre-glycine challenge drink, 60 minutes post challenge drink, 80 minutes post challenge drink, 100 minutes post challenge drink, and 120 minutes post challenge drink (0.4 g/kg up to max of 30 g); and 2) IN WEEK 6 OF OPEN-LABEL GLYCINE TREATMENT: pre-glycine dose, and 60 minutes, 80 minutes, 100 minutes and 120 minutes post daily dose of glycine. Measured in posterior occipital cortex (NCT01720316)
Timeframe: baseline (pre-challenge, 60, 80, 100, 120 minutes post-challenge), and week 6 of glycine (pre-dose and 60, 80, 100, 120 minutes post-dose
| Intervention | ratio (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline - pre-challenge drink | Baseline 60 minutes post challenge drink | Baseline 80 minutes post challenge drink | Baseline 100 minutes post challenge drink | Baseline 120 minutes post challenge drink | Week 6 of glycine - pre-glycine dose | Week 6 of glycine - 60 minutes post glycine dose | Week 6 of glycine - 80 minutes post glycine dose | Week 6 of glycine - 100 minutes post glycine dose | Week 6 of glycine - 120 minutes post glycine dose | |
| Subject 2:Brain Glycine/CR Ratio at Baseline/Week 6 of Glycine | 0.5691 | 0.3918 | 0.6428 | 0.6363 | 0.9559 | 0.3235 | 0.3807 | 0.5591 | 0.4142 | 0.3545 |
| Subject1: Brain Glycine/CR Ratio at Baseline/Week 6 of Glycine | 0.2558 | 0.6157 | 0.6631 | 0.5938 | 0.6953 | 0.6573 | 0.2983 | 0.4577 | 0.5751 | 0.3842 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within and after each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPRS at baseline | BPRS at 2 weeks intervention 1 | BPRS at 4 weeks intervention 1 | BPRS at 6 weeks intervention 1 | BPRS, end of washout1 | BPRS at 2 weeks intervention 2 | BPRS at 4 weeks intervention 2 | BPRS at 6 weeks intervention 2 | BPRS, end of washout2 | BPRS at 2 weeks open label | BPRS at 4 weeks open label | BPRS at 6 weeks open label | BPRS, end of washout3 | |
| Glycine, Then Placebo | 39 | 38 | 32 | 21 | 22 | 37 | 31 | 37 | 32 | 23 | 22 | 21 | 19 |
| Placebo, Then Glycine | 46 | 38 | 39 | 28 | 34 | 32 | 20 | 23 | 24 | 20 | 18 | 19 | 23 |
Clinical Global Impression (CGI) severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT01720316)
Timeframe: CGI at baseline and at 2 weeks, 4 weeks, and 6 weeks per treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI severity score at baseline | CGI severity score at 2 weeks intervention 1 | CGI severity score at 4 weeks intervention 1 | CGI severity score at 6 weeks intervention 1 | CGI severity score, end of washout1 | CGI severity score at 2 weeks intervention 2 | CGI severity score at 4 weeks intervention 2 | CGI severity score at 6 weeks intervention 2 | CGI severity score, end of washout2 | CGI severity score at 2 weeks open label | CGI severity score at 4 weeks open label | CGI severity score at 6 weeks open label | CGI severity score, end of washout3 | |
| Glycine, Then Placebo | 4 | 4 | 3 | 2 | 2 | 4 | 4 | 4 | 4 | 3 | 3 | 2 | 2 |
| Placebo, Then Glycine | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 2 |
Clinical Global Impression (CGI) therapeutic effect scores measure degree of improvement as marked (1), moderate (5), minimal (9) or unchanged/worse (13). (NCT01720316)
Timeframe: at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | score (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI therapeutic effect at 2 weeks intervention 1 | CGI therapeutic effect at 4 weeks intervention 1 | CGI therapeutic effect at 6 weeks intervention 1 | CGI therapeutic effect, end of washout1 | CGI therapeutic effect at 2 weeks intervention 2 | CGI therapeutic effect at 4 weeks intervention 2 | CGI therapeutic effect at 6 weeks intervention 2 | CGI therapeutic effect, end of washout2 | CGI therapeutic effect at 2 weeks open label | CGI therapeutic effect at 4 weeks open label | CGI therapeutic effect at 6 weeks open label | CGI therapeutic effect, end of washout3 | |
| Glycine, Then Placebo | 13 | 5 | 5 | 5 | 13 | 13 | 13 | 13 | 5 | 5 | 1 | 1 |
| Placebo, Then Glycine | 5 | 5 | 5 | 5 | 13 | 5 | 5 | 5 | 1 | 1 | 1 | 1 |
Hamilton Depression Scale measures severity of depression symptoms. The sum of ratings for 9 depression symptoms are measured on a scale from 0-2 with 0 meaning no symptoms and 2 meaning some level of severity of that specific symptom. The rating for 1 depression symptom is measured on a scale from 0-3 with 0 meaning no symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms are measured on a scale from 0-4 with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depression symptoms at baseline | Depression symptoms at 2 weeks intervention 1 | Depression symptoms at 4 weeks intervention 1 | Depression symptoms at 6 weeks intervention 1 | Depression symptoms, end of washout1 | Depression symptoms at 2 weeks intervention 2 | Depression symptoms at 4 weeks intervention 2 | Depression symptoms at 6 weeks intervention 2 | Depression symptoms, end of washout2 | Depression symptoms at 2 weeks open label | Depression symptoms at 4 weeks open label | Depression symptoms at 6 weeks open label | Depression symptoms, end of washout3 | |
| Glycine, Then Placebo | 18 | 17 | 11 | 3 | 1 | 19 | 5 | 7 | 3 | 2 | 2 | 1 | 2 |
| Placebo, Then Glycine | 12 | 5 | 5 | 0 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 |
Plasma glycine levels; normal range is 122-467 nM/mL (NCT01720316)
Timeframe: At baseline, during glycine treatment, during placebo treatment and during open-label glycine
| Intervention | nM/mL (Number) | |||
|---|---|---|---|---|
| Baseline | Glycine double-blind | Placebo | Glycine open-label | |
| Glycine Then Placebo | 216 | 410 | 194 | 516 |
| Placebo Then Glycine | 271 | 761 | 347 | 634 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of ratings for 7 symptoms of mania is measured on a scale from 0-4 and the sum of 4 symptoms of mania is measured on a scale from 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Manic symptoms at baseline | Manic symptoms at 2 weeks intervention 1 | Manic symptoms at 4 weeks intervention 1 | Manic symptoms at 6 weeks intervention 1 | Manic symptoms, end of washout1 | Manic symptoms at 2 weeks intervention 2 | Manic symptoms at 4 weeks intervention 2 | Manic symptoms at 6 weeks intervention 2 | Manic symptoms, end of washout2 | Manic symptoms at 2 weeks open label | Manic symptoms at 4 weeks open label | Manic symptoms at 6 weeks open label | Manic symptoms, end of washout3 | |
| Glycine, Then Placebo | 4 | 1 | 0 | 0 | 0 | 17 | 0 | 2 | 2 | 1 | 0 | 0 | 0 |
| Placebo, Then Glycine | 7 | 7 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Scores on each of 8 domains of cognitive function (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, social cognition, overall composite). Scores are T scores ranging from 0-100, with 50 representing the mean for a population based on a normal distribution; standard deviation of 10. Only overall composite score is entered. (NCT01720316)
Timeframe: At baseline, during glycine treatment, during placebo treatment and during open-label glycine
| Intervention | units on a scale (Number) | |
|---|---|---|
| Participant 1 | Participant 2 | |
| Baseline | 45 | 48 |
| Composite Score on Glycine, Double-blind | 52 | 52 |
| Composite Score on Glycine, Open-label | 49 | 46 |
| Composite Score on Placebo | 52 | 55 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms are measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period and after each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive symptoms at baseline | Positive symptoms at 2 weeks intervention 1 | Positive symptoms at 4 weeks intervention 1 | Positive symptoms at 6 weeks intervention 1 | Positive symptoms, end of washout1 | Positive symptoms at 2 weeks intervention 2 | Positive symptoms at 4 weeks intervention 2 | Positive symptoms at 6 weeks intervention 2 | Positive symptoms, end of washout2 | Positive symptoms at 2 weeks open label | Positive symptoms at 4 weeks open label | Positive symptoms at 6 weeks open label | Positive symptoms, end of washout3 | |
| Glycine, Then Placebo | 13 | 12 | 9 | 8 | 7 | 12 | 11 | 14 | 14 | 9 | 9 | 7 | 7 |
| Placebo, Then Glycine | 19 | 20 | 19 | 13 | 13 | 12 | 10 | 11 | 11 | 8 | 7 | 8 | 8 |
Auditory evoked potential amplitude: P50 ratio (P50 S2/S1) (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | ratio (Number) | |
|---|---|---|
| P50 ratio: Baseline | P50 ratio: Week 8 of DCS | |
| First Open Label DCS | 44.51 | 30 |
Auditory evoked potential amplitude: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz; P50 S1 and S2; mismatch negativity (MMN) at fz and cz. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | microvolts (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 at fz: Baseline | P300 at cz: Baseline | P300 at pz: Baseline | N100 at fz: Baseline | N100 at cz: Baseline | P200 at fz: Baseline | P200 at cz: Baseline | P50 S1: Baseline | P50 S2: Baseline | MMN at fz: Baseline | MMN at cz: Baseline | P300 at fz: Week 8 of DCS | P300 at cz: Week 8 of DCS | P300 at pz: Week 8 of DCS | N100 at fz: Week 8 of DCS | N100 at cz: Week 8 of DCS | P200 at fz: Week 8 of DCS | P200 at cz: Week 8 of DCS | P50 S1: Week 8 of DCS | P50 S2: Week 8 of DCS | MMN at fz: Week 8 of DCS | MMN at cz: Week 8 of DCS | |
| First Open Label DCS | -0.635 | 6.529 | 5.340 | -3.926 | -3.615 | 1.662 | 6.591 | 2.759 | 1.23 | -3.356 | -4.130 | 3.030 | 6.810 | 6.620 | -3.260 | -3.940 | 8.200 | 8.160 | 1.36 | 0.4 | -3.330 | -1.540 |
Auditory evoked potential gamma: G40 hz phase locking at fz and cz; G30 hz phase locking at fz and cz; G20 hz phase locking at fz and cz (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | microvolts squared (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| G40 hz phase locking at fz: Baseline | G40 hz phase locking at cz: Baseline | G30 hz phase locking at fz: Baseline | G30 hz phase locking at cz: Baseline | G20 hz phase locking at fz: Baseline | G20 hz phase locking at cz: Baseline | G40 hz phase locking at fz: Week 8 of DCS | G40 hz phase locking at cz: Week 8 of DCS | G30 hz phase locking at fz: Week 8 of DCS | G30 hz phase locking at cz: Week 8 of DCS | G20 hz phase locking at fz: Week 8 of DCS | G20 hz phase locking at cz: Week 8 of DCS | |
| First Open Label DCS | 0.135 | 0.168 | 0.190 | 0.163 | 0.023 | 0.030 | 0.344 | 0.381 | 0.168 | 0.19 | 0.01 | -0.01 |
Auditory evoked potential latency: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | msec (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 at fz: Baseline | P300 at cz: Baseline | P300 at pz: Baseline | N100 at fz: Baseline | N100 at cz: Baseline | P200 at fz: Baseline | P200 at cz: Baseline | P300 at fz: Week 8 of DCS | P300 at cz: Week 8 of DCS | P300 at pz: Week 8 of DCS | N100 at fz: Week 8 of DCS | N100 at cz: Week 8 of DCS | P200 at fz: Week 8 of DCS | P200 at cz: Week 8 of DCS | |
| First Open Label DCS | 279.297 | 279.297 | 279.297 | 97.656 | 91.797 | 197.266 | 193.359 | 294.920 | 294.000 | 294 | 87.9 | 88.000 | 212.890 | 212.000 |
Proton magnetic resonance spectroscopy at 4T: brain glycine/CR ratio. Participants were assessed at baseline (pre-glycine challenge dose and 60, 80, 100 and 120 minutes post glycine dose) and in week 8 of of open-label DCS treatment: pre-DCS dose, and 60, 80, 100 and 120 minutes post DCS dose. Measured in posterior occipital cortex. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | ratio (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Baseline at 60 minutes | Baseline at 80 minutes | Baseline at 100 minutes | Baseline at 120 minutes | Week 8 of DCS: Baseline | Week 8 of DCS: 60 minutes | Week 8 of DCS: 80 minutes | Week 8 of DCS: 100 minutes | Week 8 of DCS: 120 minutes | |
| Open Label DCS | 0.41245 | 0.50375 | 0.65295 | 0.61505 | 0.8256 | 0.10977 | 0.248885 | 0.32609 | 0.32052 | 0.312155 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline BPRS | 2 weeks BPRS | 4 weeks BPRS | 6 weeks BPRS | 8 weeks BPRS | 10 weeks BPRS | 12 weeks BPRS | 14 weeks BPRS | 16 weeks BPRS | 18 weeks BPRS | 20 weeks BPRS | 22 weeks BPRS | 24 weeks BPRS | |
| First Open Label DCS | 37 | 25 | 26 | 24 | 24.5 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 31.5 | 30.5 | 28 | 25.5 | 26 | 26.5 | 26 | 25.5 | 28.5 | 27 | 25 | 24.5 | 26.5 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline BPRS for first intervention | 2 weeks BPRS for first intervention | 4 weeks BPRS for first intervention | 6 weeks BPRS for first intervention | Baseline BPRS for second intervention | 2 weeks BPRS for second intervention | 4 weeks BPRS for second intervention | 6 weeks BPRS for second intervention | |
| DCS First, Then Placebo | 26 | 25 | 25 | 26 | 39 | 45 | 45 | 38 |
| Placebo First, Then DCS | 29 | 35 | 33 | 35 | 36 | 30 | 27 | 28 |
CGI severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline CGI | 2 weeks CGI | 4 weeks CGI | 6 weeks CGI | 8 weeks CGI | 10 weeks CGI | 12 weeks CGI | 14 weeks CGI | 16 weeks CGI | 18 weeks CGI | 20 weeks CGI | 22 weeks CGI | 24 weeks CGI | |
| First Open Label DCS | 4 | 2 | 2 | 2 | 2 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 3 | 2.5 | 2 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
CGI severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline CGI for first intervention | 2 weeks CGI for first intervention | 4 weeks CGI for first intervention | 6 weeks CGI for first intervention | Baseline CGI for second intervention | 2 weeks CGI for second intervention | 4 weeks CGI for second intervention | 6 weeks CGI for second intervention | |
| DCS First, Then Placebo | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 |
| Placebo First, Then DCS | 1 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
Hamilton Depression Scale (HAM) measures severity of depression symptoms. The sum of the ratings for 9 depression symptoms is measured on a scale of 0-2 with 0 meaning no depression symptoms and 2 meaning some level of severity of that specific symptom. The rating for one depression symptom is measured on a scale of 0-3 with 0 meaning no depression symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms is measured on a scale of 0-4, with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. Higher scores indicate worse depression symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline HAM | 2 weeks HAM | 4 weeks HAM | 6 weeks HAM | 8 weeks HAM | 10 weeks HAM | 12 weeks HAM | 14 weeks HAM | 16 weeks HAM | 18 weeks HAM | 20 weeks HAM | 22 weeks HAM | 24 weeks HAM | |
| First Open Label DCS | 5 | 1.5 | 1 | 0.5 | 1.5 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 0.5 | 1 | 1 | 0 | 2.5 | 0 | 0 | 0 | 3.5 | 0 | 0 | 0 | 0 |
Hamilton Depression Scale (HAM) measures severity of depression symptoms. The sum of the ratings for 9 depression symptoms is measured on a scale of 0-2 with 0 meaning no depression symptoms and 2 meaning some level of severity of that specific symptom. The rating for one depression symptom is measured on a scale of 0-3 with 0 meaning no depression symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms is measured on a scale of 0-4, with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. Higher scores indicate worse depression symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline HAM for first intervention | 2 weeks HAM for first intervention | 4 weeks HAM for first intervention | 6 weeks HAM for first intervention | Baseline HAM for second intervention | 2 weeks HAM for second intervention | 4 weeks HAM for second intervention | 6 weeks HAM for second intervention | |
| DCS First, Then Placebo | 0 | 1 | 0 | 0 | 2 | 12 | 9 | 2 |
| Placebo First, Then DCS | 4 | 5 | 2 | 10 | 0 | 0 | 0 | 0 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of the ratings for 7 symptoms of mania is measured on a scale of 0-4 and the sumof 4 symptoms of mania is measured on a scale of 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline YMRS | 2 weeks YMRS | 4 weeks YMRS | 6 weeks YMRS | 8 weeks YMRS | 10 weeks YMRS | 12 weeks YMRS | 14 weeks YMRS | 16 weeks YMRS | 18 weeks YMRS | 20 weeks YMRS | 22 weeks YMRS | 24 weeks YMRS | |
| First Open Label DCS | 2 | 1 | 1 | 0 | 0 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of the ratings for 7 symptoms of mania is measured on a scale of 0-4 and the sumof 4 symptoms of mania is measured on a scale of 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline YMRS for first intervention | 2 weeks YMRS for first intervention | 4 weeks YMRS for first intervention | 6 weeks YMRS for first intervention | Baseline YMRS for second intervention | 2 weeks YMRS for second intervention | 4 weeks YMRS for second intervention | 6 weeks YMRS for second intervention | |
| DCS First, Then Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo First, Then DCS | 1 | 0 | 0 | 0 | 4 | 1 | 1 | 1 |
Scores on each of 8 domains of cognitive function (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, social cognition, overall composite). Scores are T scores ranging from 0-100, with 50 representing the mean for a population based on a normal distribution, standard deviation of 10. Higher scores signify better functioning. (NCT02304432)
Timeframe: Baseline and Week 8 of open-label DCS treatment
| Intervention | T scores (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Processing Speed | Baseline Attention/Vigilance | Baseline Working Memory | Baseline Verbal Learning | Baseline Visual Learning | Baseline Reasoning/Problem Solving | Baseline Social Cognition | Baseline Overall Composite Score | Week 8 of open-label DCS Processing Speed | Week 8 of open-label DCS Attention/Vigilance | Week 8 of open-label DCS Working Memory | Week 8 of open-label DCS Verbal Learning | Week 8 of open-label DCS Visual Learning | Week 8 of open-label DCS Reasoning/Problem Solving | Week 8 of open-label DCS Social Cognition | Week 8 of open-label DCS Overall Composite Score | |
| Open Label DCS | 48.5 | 44.5 | 38.5 | 54 | 50.5 | 52.5 | 48 | 46.5 | 52.5 | 47.5 | 50.5 | 43.5 | 54.5 | 66.5 | 44.5 | 51.5 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms.The sum of ratings for seven negative symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline positive | Baseline negative | 2 weeks positive | 2 weeks negative | 4 weeks positive | 4 weeks negative | 6 weeks positive | 6 weeks negative | 8 weeks positive | 8 weeks negative | 10 weeks positive | 10 weeks negative | 12 weeks positive | 12 weeks negative | 14 weeks positive | 14 weeks negative | 16 weeks positive | 16 weeks negative | 18 weeks positive | 18 weeks negative | 20 weeks positive | 20 weeks negative | 22 weeks positive | 22 weeks negative | 24 weeks positive | 24 weeks negative | |
| First Open Label DCS | 14.5 | 14.5 | 10 | 12 | 10.5 | 12 | 9 | 12 | 9 | 12 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 11 | 14 | 11 | 14 | 10.5 | 13.5 | 9 | 13 | 9.5 | 12 | 10.5 | 13 | 11 | 12 | 10 | 12 | 10.5 | 12 | 10.5 | 12 | 10.5 | 12 | 9.5 | 12 | 10 | 12 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms.The sum of ratings for seven negative symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline positive for first intervention | Baseline negative symptoms for first intervention | 2 weeks positive for first intervention | 2 weeks negative for first intervention | 4 weeks positive for first intervention | 4 weeks negative for first intervention | 6 weeks positive for first intervention | 6 weeks negative for first intervention | Baseline positive for second intervention | Baseline negative for second intervention | 2 weeks positive for second intervention | 2 weeks negative for second intervention | 4 weeks positive for second intervention | 4 weeks negative for second intervention | 6 weeks positive for second intervention | 6 weeks negative for second intervention | |
| DCS First, Then Placebo | 10 | 15 | 10 | 15 | 10 | 15 | 10 | 15 | 15 | 18 | 15 | 18 | 15 | 18 | 14 | 18 |
| Placebo First, Then DCS | 11 | 9 | 12 | 15 | 11 | 13 | 13 | 13 | 13 | 13 | 10 | 11 | 9 | 11 | 9 | 11 |
Brain and plasma glycine levels are measured with proton magnetic resonance spectroscopy at 4T and analytically, respectively. Because glycine doses were limited to 30 g to avoid nausea and vomiting, some subjects with higher weights were administered lower doses per body weight of glycine (g/kg). Therefore, we corrected MRS data by the actual glycine dose administered (g/kg) to account for dosing differences. (NCT01610011)
Timeframe: For up to 2 hours
| Intervention | Percent brain glycine/creatine increase (Mean) |
|---|---|
| Glycine Administration Controls | 393 |
| Glycine Administration GLDC Mutation Subjects | 677 |
The Heinrichs-Carpenter Quality of Life Scale is a testing device. It has a range of possible scores, 0-126 used to evaluate social functioning & behavior in patients with schizophrenia-lower scores represent poorer mental health. (NCT00237809)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| D-serine/Control | 67.26 |
| Placebo/Cog Rehab | 68.30 |
| D-serine/Cog Rehab | 63.25 |
| Placebo/Control | 63.92 |
The Hopkins Verbal Learning Test is designed to assess verbal learning and memory (immediate recall, delayed recall, delayed recognition). The assessment takes approximately 5-10 minutes with a 25-minute delay to complete and 2 minutes to score. The greater the score, the greater the measured recall. The score ranges from 0 to 24. (NCT00237809)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| D-serine/Control | 20.74 |
| Placebo/Cog Rehab | 19.80 |
| D-serine/Cog Rehab | 20.42 |
| Placebo/Control | 21.45 |
The PANSS is a handscored instrument. It uses 25 PANSS items organized into five scales: Negative, Positive, Dysphoric Mood, Activation, and Autistic Preoccupation. The PANSS is based on findings that schizophrenia comprises at least two distinct syndromes. The positive syndrome consists of productive symptoms, while the negative syndrome consists of deficit features. This distinction is useful when developing treatment plans because you can focus on the type of symptoms the patient is experiencing. It is also useful when studying the effects of medication (e.g., in clinical drug trials) because it allows you to determine which type of symptoms are being affected. PANSS Total score minimum = 30, maximum = 210. The greater the score, the greater the symptoms. (NCT00237809)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| D-serine/Control | 53.30 |
| Placebo/Cog Rehab | 52.01 |
| D-serine/Cog Rehab | 53.79 |
| Placebo/Control | 53.96 |
Simpson-Angus Scale (SAS) is a 10-item rating scale that has been used widely for assessment in both clinical practice and research settings. Items are rated for severity on a 0-4 scale, with definitions given for each anchor point. The highest possible score is 40. (NCT00237809)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| D-serine/Control | 1.41 |
| Placebo/Cog Rehab | 0.72 |
| D-serine/Cog Rehab | 1.04 |
| Placebo/Control | 1.81 |
The Spatial Span subtest of the Wechsler Memory Scale can be used as an indicator of working memory and visuospatial processing. An increase in severity of impairment results in a decrease in Spatial Span Total Score. The range is 1 to 28. (NCT00237809)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| D-serine/Control | 13.59 |
| Placebo/Cog Rehab | 13.88 |
| D-serine/Cog Rehab | 13.21 |
| Placebo/Control | 13.58 |
The UCSD Performance-Based Skills Assessment (UPSA) is a role-play test designed to evaluate a person's functional capacity in two selected areas of basic living skills. These areas include Finance and Communication. Subjects being tested utilize props to demonstrate how they perform everyday activities and are assessed on their actual performance. The higher the score, the better the performance of an individual. The scores range from 0 to 100. (NCT00237809)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| D-serine/Control | 34.19 |
| Placebo/Cog Rehab | 32.80 |
| D-serine/Cog Rehab | 32.60 |
| Placebo/Control | 31.39 |
"The WCST allows the clinician to speculate to the following frontal lobe functions: strategic planning, organized searching, utilizing environmental feedback to shift cognitive sets, directing behavior toward achieving a goal, and modulating impulsive responding. The test can be administered to those from 6.5 years to 89 years of age.The test takes approximately 12-20 minutes to carry out and generates a number of psychometric scores, including numbers, percentages, and percentiles of: categories achieved, trials, errors, and perseverative errors. Can be interpreted as: the greater the percentage, the greater the measured ability." (NCT00237809)
Timeframe: 12 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| D-serine/Control | 38.43 |
| Placebo/Cog Rehab | 35.79 |
| D-serine/Cog Rehab | 43.14 |
| Placebo/Control | 39.57 |
46 reviews available for glycine and Schizophrenia
| Article | Year |
|---|---|
Update on Oxytocin, Phosphodiesterase, Neurokinin, Glycine as a Therapeutic Approach in the Treatment of Schizophrenia.
Topics: Adult; Antipsychotic Agents; Glycine; Humans; Oxytocin; Phosphoric Diester Hydrolases; Schizophrenia | 2023 |
Glycine transporters in schizophrenia. A new hope or informational noise?
Topics: Glycine; Glycine Plasma Membrane Transport Proteins; Humans; Receptors, N-Methyl-D-Aspartate; Sarcos | 2022 |
Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: a hypothesis.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Glycine; Humans; Parkinson Disease; Recep | 2013 |
Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.
Topics: Alcoholism; Animals; Drugs, Investigational; Glycine; Glycine Plasma Membrane Transport Proteins; Hu | 2013 |
Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Antipsychotic Agents; Cognition Disorders; Glycine; Humans; | 2014 |
The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond.
Topics: Animals; Antipsychotic Agents; Cognition Disorders; Dopamine; Glycine; Humans; Receptors, N-Methyl-D | 2015 |
Pharmacological treatment of negative symptoms in schizophrenia.
Topics: Antidepressive Agents; Antipsychotic Agents; Excitatory Amino Acid Agents; Glycine; Glycine Agents; | 2015 |
Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
Topics: Animals; Antipsychotic Agents; Brain; Drug Discovery; Glycine; Glycine Plasma Membrane Transport Pro | 2015 |
[Metabolism and functions of brain D-serine in mammals: relevance to neuropsychiatric disorders].
Topics: Animals; Brain; Drug Design; Glycine; Humans; Isomerism; Mental Disorders; Nervous System Diseases; | 2008 |
Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
Topics: Allosteric Regulation; Animals; Glycine; Glycine Plasma Membrane Transport Proteins; Humans; Recepto | 2008 |
Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification.
Topics: Animals; Antipsychotic Agents; Biological Transport; Clinical Trials as Topic; Drug Design; Drug Eva | 2009 |
The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.
Topics: Animals; Glycine; Humans; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 2010 |
Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.
Topics: Amino Acids; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combinat | 2010 |
Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.
Topics: Amino Acids; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combinat | 2010 |
Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.
Topics: Amino Acids; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combinat | 2010 |
Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.
Topics: Amino Acids; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combinat | 2010 |
[Stimulating glutamatergic neurons as a potential novel therapeutic avenue for schizophrenia].
Topics: Animals; Drug Design; Glutamates; Glycine; Humans; Neurons; Receptors, N-Methyl-D-Aspartate; Sarcosi | 2010 |
[Analysis of mouse strain-dependent prepulse inhibition points to a role for Shmt1 (SHMT1) in mice and in schizophrenia].
Topics: Animals; Glycine; Glycine Hydroxymethyltransferase; Humans; Mice; Mice, Inbred Strains; Neural Inhib | 2010 |
[Development of a novel pharmacotherapy targeted at the N-methyl-D-aspartate receptor-D-serine system for schizophrenia].
Topics: Animals; Clinical Trials as Topic; Drug Design; Glycine; Humans; Molecular Targeted Therapy; Phencyc | 2010 |
Glycine transporter-1: a new potential therapeutic target for schizophrenia.
Topics: Animals; Antipsychotic Agents; Clinical Trials, Phase II as Topic; Glycine; Glycine Plasma Membrane | 2011 |
Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Middle Aged; Ran | 2011 |
Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain; Brain Mapping; Cerebral Cortex; Cognition Disorders; Contingen | 2012 |
Glycine transport inhibitors in the treatment of schizophrenia.
Topics: Animals; Glycine; Glycine Plasma Membrane Transport Proteins; Humans; Piperazines; Receptors, N-Meth | 2012 |
Biomarkers for antipsychotic therapies.
Topics: Animals; Antipsychotic Agents; Biomarkers; Clinical Trials as Topic; Glycine; Glycine Plasma Membran | 2012 |
Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1).
Topics: Glycine; Glycine Plasma Membrane Transport Proteins; Humans; Schizophrenia | 2013 |
Glycine modulators in schizophrenia.
Topics: Animals; Glycine; Humans; Receptors, Glycine; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 2002 |
Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis.
Topics: Amino Acid Substitution; Case-Control Studies; Genetic Variation; Glycine; Homozygote; Humans; Recep | 2003 |
NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia.
Topics: Anesthetics; Animals; Clinical Trials as Topic; Glutamic Acid; Glycine; Humans; Models, Neurological | 2004 |
The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia.
Topics: Animals; Clozapine; Cognition Disorders; Double-Blind Method; GABA Antagonists; Glycine; Humans; Ran | 2004 |
Effects of D-cycloserine on negative symptoms in schizophrenia.
Topics: Affect; Antimetabolites; Antipsychotic Agents; Cognition Disorders; Cycloserine; Diagnostic and Stat | 2004 |
Effects of D-cycloserine on negative symptoms in schizophrenia.
Topics: Affect; Antimetabolites; Antipsychotic Agents; Cognition Disorders; Cycloserine; Diagnostic and Stat | 2004 |
Effects of D-cycloserine on negative symptoms in schizophrenia.
Topics: Affect; Antimetabolites; Antipsychotic Agents; Cognition Disorders; Cycloserine; Diagnostic and Stat | 2004 |
Effects of D-cycloserine on negative symptoms in schizophrenia.
Topics: Affect; Antimetabolites; Antipsychotic Agents; Cognition Disorders; Cycloserine; Diagnostic and Stat | 2004 |
Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis.
Topics: Clozapine; Cycloserine; Dioxoles; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid A | 2005 |
N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.
Topics: Animals; Antipsychotic Agents; Glycine; Humans; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Seri | 2005 |
Glutamate-based therapeutic approaches: inhibitors of glycine transport.
Topics: Animals; Benzamides; Central Nervous System; Clinical Trials as Topic; Dopamine; Drug Evaluation, Pr | 2006 |
Glycine transporter type-1 and its inhibitors.
Topics: Animals; Antipsychotic Agents; Anxiety Disorders; Glycine; Glycine Plasma Membrane Transport Protein | 2006 |
Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
Topics: Antimetabolites; Antipsychotic Agents; Clozapine; Cycloserine; Drug Therapy, Combination; Glutamic A | 2006 |
The role of group I metabotropic glutamate receptors in schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain; Disease Models, Animal; Glycine; Humans; Mice; Mice, Knockout; | 2007 |
Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.
Topics: Allosteric Regulation; Animals; Antipsychotic Agents; Benzamides; Benzimidazoles; Brain; Glycine; Gl | 2006 |
[Update on the animal models of schizophrenia].
Topics: Animals; Behavior, Animal; Brain; Disease Models, Animal; Drug Design; Excitatory Amino Acid Antagon | 2006 |
Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptors.
Topics: Amino Acid Transport Systems; Antipsychotic Agents; Glycine; Glycine Agents; Humans; Receptors, N-Me | 2007 |
Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
Topics: Acetamides; Alanine; Antipsychotic Agents; Clozapine; Cognition; Cycloserine; Dopamine Agents; Drug | 2008 |
Glycine transporter inhibitors as therapeutic agents for schizophrenia.
Topics: Animals; Benzamides; Glutamic Acid; Glycine; Glycine Plasma Membrane Transport Proteins; Humans; Pip | 2006 |
Glycine: a possible role in lithium's action and affective illness.
Topics: Amino Acid Metabolism, Inborn Errors; Animals; Autistic Disorder; Bipolar Disorder; Brain Chemistry; | 1983 |
The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications.
Topics: Alzheimer Disease; Animals; Binding Sites; Cerebrovascular Disorders; Epilepsy; Glycine; Humans; Neu | 1998 |
[Glycine therapy of schizophrenia; its rationale and a review of clinical trials].
Topics: Acetamides; Alanine; Amino Acid Transport Systems, Neutral; Animals; Carrier Proteins; Cycloserine; | 1998 |
Glycine agonists: what can they teach us about schizophrenia?
Topics: Adolescent; Adult; Animals; Brain; Child; Clinical Trials as Topic; Cycloserine; Glycine; Humans; Ra | 1999 |
Glycine agonists: what can they teach us about schizophrenia?
Topics: Adolescent; Adult; Animals; Brain; Child; Clinical Trials as Topic; Cycloserine; Glycine; Humans; Ra | 1999 |
Glycine agonists: what can they teach us about schizophrenia?
Topics: Adolescent; Adult; Animals; Brain; Child; Clinical Trials as Topic; Cycloserine; Glycine; Humans; Ra | 1999 |
Glycine agonists: what can they teach us about schizophrenia?
Topics: Adolescent; Adult; Animals; Brain; Child; Clinical Trials as Topic; Cycloserine; Glycine; Humans; Ra | 1999 |
[Endogenous D-serine in mammalian brains].
Topics: Animals; Brain; Glutamic Acid; Glycine; Humans; Racemases and Epimerases; Rats; Receptors, N-Methyl- | 2000 |
Treatment of negative and cognitive symptoms.
Topics: Antimetabolites; Antipsychotic Agents; Cognition Disorders; Cycloserine; Glycine; Humans; Receptors, | 1999 |
[Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
Topics: Animals; Antipsychotic Agents; Corpus Callosum; Dizocilpine Maleate; Drug Design; Glutamates; Glutat | 2002 |
A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine.
Topics: Glutamates; Glycine; Humans; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotransmitter; Schizophr | 1989 |
30 trials available for glycine and Schizophrenia
| Article | Year |
|---|---|
The effects of glycine on auditory mismatch negativity in schizophrenia.
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Case-Control Studies; Contingent Negative Variati | 2018 |
Association between increased serum d-serine and cognitive gains induced by intensive cognitive training in schizophrenia.
Topics: Adult; Cognitive Dysfunction; Cognitive Remediation; Female; Glycine; Humans; Male; Middle Aged; Neu | 2019 |
Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies.
Topics: Administration, Oral; Adult; Alzheimer Disease; Animals; Area Under Curve; Cell Line; Dose-Response | 2018 |
Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP).
Topics: Adolescent; Adult; Antipsychotic Agents; Case-Control Studies; Chi-Square Distribution; Chromatograp | 2008 |
Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Female; Genotype; Glycine; Humans; | 2009 |
Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain; Color Perception; Dose-Response Relationship, Drug; | 2013 |
Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms.
Topics: Adult; Chromatography, High Pressure Liquid; Depressive Disorder, Major; Female; Glycine; Humans; Ma | 2004 |
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Behavioral Symptoms; Benzodiazepines; Cross-Over Studies; Dose-Response | 2004 |
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
Topics: Adult; Antimetabolites; Antipsychotic Agents; Chlorpromazine; Cycloserine; Female; Glycine; Humans; | 2004 |
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
Topics: Adult; Antimetabolites; Antipsychotic Agents; Chlorpromazine; Cycloserine; Female; Glycine; Humans; | 2004 |
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
Topics: Adult; Antimetabolites; Antipsychotic Agents; Chlorpromazine; Cycloserine; Female; Glycine; Humans; | 2004 |
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
Topics: Adult; Antimetabolites; Antipsychotic Agents; Chlorpromazine; Cycloserine; Female; Glycine; Humans; | 2004 |
Effects of D-cycloserine on negative symptoms in schizophrenia.
Topics: Affect; Antimetabolites; Antipsychotic Agents; Cognition Disorders; Cycloserine; Diagnostic and Stat | 2004 |
Effects of D-cycloserine on negative symptoms in schizophrenia.
Topics: Affect; Antimetabolites; Antipsychotic Agents; Cognition Disorders; Cycloserine; Diagnostic and Stat | 2004 |
Effects of D-cycloserine on negative symptoms in schizophrenia.
Topics: Affect; Antimetabolites; Antipsychotic Agents; Cognition Disorders; Cycloserine; Diagnostic and Stat | 2004 |
Effects of D-cycloserine on negative symptoms in schizophrenia.
Topics: Affect; Antimetabolites; Antipsychotic Agents; Cognition Disorders; Cycloserine; Diagnostic and Stat | 2004 |
Dopamine D3 receptor Ser9Gly polymorphism and risperidone response.
Topics: Adult; Amino Acid Substitution; Antipsychotic Agents; China; DNA; Dose-Response Relationship, Drug; | 2005 |
Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia.
Topics: Adult; Antipsychotic Agents; Chromatography, High Pressure Liquid; Clozapine; Female; Glycine; Human | 2005 |
Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results.
Topics: Adult; Analysis of Variance; Clozapine; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combi | 2005 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agen | 2007 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agen | 2007 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agen | 2007 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agen | 2007 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agen | 2007 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agen | 2007 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agen | 2007 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agen | 2007 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agen | 2007 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agen | 2007 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agen | 2007 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agen | 2007 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agen | 2007 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agen | 2007 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agen | 2007 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agen | 2007 |
Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting.
Topics: Adult; Antipsychotic Agents; Female; Glycine; Humans; Male; Pharmacogenetics; Polymorphism, Genetic; | 2008 |
Acute high-dose glycine attenuates mismatch negativity (MMN) in healthy human controls.
Topics: Acoustic Stimulation; Adult; Cognition; Cross-Over Studies; Double-Blind Method; Electrophysiology; | 2008 |
Cerebrospinal fluid D-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Glycine; Humans; Male; Middle Aged; Olanzapine; Schizo | 2008 |
Pharmacological augmentation of NMDA receptor function for treatment of schizophrenia.
Topics: Adult; Double-Blind Method; Glycine; Humans; Male; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 1995 |
Amelioration of negative symptoms in schizophrenia by glycine.
Topics: Adult; Double-Blind Method; Glycine; Humans; Male; Placebos; Receptors, N-Methyl-D-Aspartate; Schizo | 1994 |
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap | 1996 |
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap | 1996 |
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap | 1996 |
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap | 1996 |
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap | 1996 |
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap | 1996 |
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap | 1996 |
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap | 1996 |
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap | 1996 |
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap | 1996 |
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap | 1996 |
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap | 1996 |
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap | 1996 |
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap | 1996 |
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap | 1996 |
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap | 1996 |
Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia.
Topics: Adult; Double-Blind Method; Female; Glycine; Humans; Male; Receptors, N-Methyl-D-Aspartate; Schizoph | 1996 |
A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cycloserine; Double-Blind Method; Drug Administration Sche | 1999 |
A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cycloserine; Double-Blind Method; Drug Administration Sche | 1999 |
A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cycloserine; Double-Blind Method; Drug Administration Sche | 1999 |
A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cycloserine; Double-Blind Method; Drug Administration Sche | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 1999 |
Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Drug Therapy, Combination; F | 1999 |
Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Drug Therapy, Combination; F | 1999 |
Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Drug Therapy, Combination; F | 1999 |
Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Drug Therapy, Combination; F | 1999 |
D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
Topics: Adult; Antimetabolites; Antipsychotic Agents; Cycloserine; Double-Blind Method; Drug Therapy, Combin | 1999 |
D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
Topics: Adult; Antimetabolites; Antipsychotic Agents; Cycloserine; Double-Blind Method; Drug Therapy, Combin | 1999 |
D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
Topics: Adult; Antimetabolites; Antipsychotic Agents; Cycloserine; Double-Blind Method; Drug Therapy, Combin | 1999 |
D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
Topics: Adult; Antimetabolites; Antipsychotic Agents; Cycloserine; Double-Blind Method; Drug Therapy, Combin | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
D-serine added to clozapine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Glycine; Humans; Receptors, N-Methyl-D-A | 1999 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; D | 2000 |
Adjunctive high-dose glycine in the treatment of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2001 |
Adjunctive high-dose glycine in the treatment of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2001 |
Adjunctive high-dose glycine in the treatment of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2001 |
Adjunctive high-dose glycine in the treatment of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2001 |
Adjunctive high-dose glycine in the treatment of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2001 |
Adjunctive high-dose glycine in the treatment of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2001 |
Adjunctive high-dose glycine in the treatment of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2001 |
Adjunctive high-dose glycine in the treatment of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2001 |
Adjunctive high-dose glycine in the treatment of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2001 |
Adjunctive high-dose glycine in the treatment of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2001 |
Adjunctive high-dose glycine in the treatment of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2001 |
Adjunctive high-dose glycine in the treatment of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2001 |
Adjunctive high-dose glycine in the treatment of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2001 |
Adjunctive high-dose glycine in the treatment of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2001 |
Adjunctive high-dose glycine in the treatment of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2001 |
Adjunctive high-dose glycine in the treatment of schizophrenia.
Topics: Adult; Amino Acids; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gl | 2001 |
Influence of some psychoactive drugs on mineral metabolism in man.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Adult; Analysis of Variance; Antipsychotic Agents; Benztro | 1973 |
The effects of L-methionine (without MAOI) in schizophrenia.
Topics: Catechols; Chronic Disease; Clinical Trials as Topic; Female; Fluorometry; Glycine; Glycols; Humans; | 1971 |
111 other studies available for glycine and Schizophrenia
| Article | Year |
|---|---|
mGlu
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition; Cognitive Dysfunction; Disease Models, A | 2021 |
Glycine attenuates impairments of stimulus-evoked gamma oscillations in the ketamine model of schizophrenia.
Topics: Evoked Potentials, Auditory; Glycine; Humans; Ketamine; Male; Receptors, N-Methyl-D-Aspartate; Schiz | 2022 |
Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management.
Topics: Amino Acids; Animals; Autism Spectrum Disorder; Cognition; Cognition Disorders; Cycloserine; Dose-Re | 2020 |
Guanidinoacetic acid as an adjunct biomarker in schizophrenia.
Topics: Biomarkers; Glycine; Humans; Schizophrenia | 2021 |
Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.
Topics: Animals; Antipsychotic Agents; Auditory Cortex; Auditory Perception; Electrodes, Implanted; Evoked P | 2018 |
In Vivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Time-Averaged Proton Magnetic Resonance Spectroscopy at 4T.
Topics: Adult; Bipolar Disorder; Brain; Case-Control Studies; Female; Glutamic Acid; Glycine; Humans; Image | 2018 |
Excitatory Amino Acids in Schizophrenia: Both What You Have, and What You Do With Them.
Topics: Brain; Excitatory Amino Acids; Glutamic Acid; Glycine; Humans; Proton Magnetic Resonance Spectroscop | 2018 |
Inhibitors of the Neutral Amino Acid Transporters ASCT1 and ASCT2 Are Effective in In Vivo Models of Schizophrenia and Visual Dysfunction.
Topics: Amino Acid Transport System ASC; Animals; Brain; Glycine; Locomotion; Male; Mice; Mice, Inbred C57BL | 2018 |
Gamma-band auditory steady-state response is associated with plasma levels of d-serine in schizophrenia: An exploratory study.
Topics: Adolescent; Adult; Case-Control Studies; Electroencephalography; Evoked Potentials, Auditory; Female | 2019 |
Cuprizone-treated mice, a possible model of schizophrenia, highlighting the simultaneous abnormalities of GABA, serine and glycine in hippocampus.
Topics: Animals; Cuprizone; Disease Models, Animal; gamma-Aminobutyric Acid; Glycine; Hippocampus; Male; Met | 2019 |
Glycine reuptake inhibition: a promising therapeutic strategy in the treatment of schizophrenia?
Topics: Animals; Antipsychotic Agents; Glycine; Glycine Plasma Membrane Transport Proteins; Humans; Schizoph | 2013 |
Therapeutics: Negative feedback.
Topics: Affect; alpha7 Nicotinic Acetylcholine Receptor; Antipsychotic Agents; Controlled Clinical Trials as | 2014 |
Clozapine and glycinamide prevent MK-801-induced deficits in the novel object recognition (NOR) test in the domestic rabbit (Oryctolagus cuniculus).
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dizocilpine Maleate; Excitatory Am | 2014 |
Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Clozapine; Female; Glutamic Acid; Glutamine; Glyc | 2014 |
Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dizocilpine | 2015 |
Glycinamide prevents MK-801-induced hyperactivity and deficits in object recognition memory in an animal model of positive and cognitive symptoms of schizophrenia.
Topics: Animals; Antipsychotic Agents; Cognition; Disease Models, Animal; Dizocilpine Maleate; Excitatory Am | 2015 |
Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Cognition; Cognition Disorders; Disease Models | 2015 |
Blockade of growth hormone secretagogue receptor 1A signaling by JMV 2959 attenuates the NMDAR antagonist, phencyclidine-induced impairments in prepulse inhibition.
Topics: Animals; Dose-Response Relationship, Drug; Glycine; Male; Phencyclidine; Prepulse Inhibition; Rats; | 2015 |
Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers.
Topics: Adult; Area Under Curve; Brain; Glycine; Glycine Plasma Membrane Transport Proteins; Healthy Volunte | 2016 |
Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia.
Topics: Animals; Behavior, Animal; Carrier Proteins; Clozapine; Disease Models, Animal; Glycine; Male; Mice; | 2008 |
Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Discrimination, Psychological; Dizocilpine Mal | 2008 |
Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Attention; Cholinergic Antagonists; Clozapine; Cognition Disorders; C | 2009 |
Association of the dopamine D3 receptor Ser9Gly and of the serotonin 2C receptor gene polymorphisms with tardive dyskinesia in Greeks with chronic schizophrenic disorder.
Topics: Amino Acid Substitution; Chronic Disease; Dyskinesias; Female; Genetic Predisposition to Disease; Gl | 2009 |
Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Brain-Derived Neurotrophic Factor; Chi-Square | 2009 |
Association analysis of glycine- and serine-related genes in a Japanese population of patients with schizophrenia.
Topics: Adult; Case-Control Studies; Chi-Square Distribution; D-Amino-Acid Oxidase; DNA Mutational Analysis; | 2009 |
Prepulse inhibition and genetic mouse models of schizophrenia.
Topics: Animals; Brain; Disease Models, Animal; Environment; Genetic Predisposition to Disease; Glutamic Aci | 2009 |
The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine.
Topics: Animals; Antipsychotic Agents; Calcium Signaling; Cell Death; Cells, Cultured; Electrophysiological | 2009 |
Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia.
Topics: Adult; Aged; Akathisia, Drug-Induced; Chlorpromazine; Cross-Sectional Studies; Cystine; Disability E | 2009 |
Genetic loss of D-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice.
Topics: Animals; Arginine; Asparagine; Aspartic Acid; Behavior, Animal; Binding Sites; Carrier Proteins; D-A | 2010 |
Complementary and alternative medicine in the treatment of schizophrenia.
Topics: Combined Modality Therapy; Complementary Therapies; Diet, Gluten-Free; Fatty Acids, Omega-3; Ginkgo | 2009 |
The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex.
Topics: Amino Acids; Animals; Antipsychotic Agents; Biogenic Monoamines; Central Nervous System Agents; Dise | 2010 |
Glycine serum level in schizophrenia: relation to negative symptoms.
Topics: Adult; Case-Control Studies; Chromatography, High Pressure Liquid; Female; Glycine; Humans; Internat | 2010 |
Ser9Gly polymorphism of the DRD3 gene is associated with worse premorbid social functioning and an earlier age of onset in female but not male schizophrenic patients.
Topics: Adolescent; Adult; Age of Onset; Child; Female; Gene Frequency; Genome-Wide Association Study; Glyci | 2010 |
Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia.
Topics: Animals; Behavior, Animal; Central Nervous System Viral Diseases; Disease Models, Animal; Dopamine; | 2010 |
Association study of DRD3 gene in schizophrenia in Mexican sib-pairs.
Topics: Adult; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Glycine; Hu | 2011 |
The NMDA receptor co-agonists, D-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex.
Topics: Animals; Brain-Derived Neurotrophic Factor; Dendrites; Gene Expression Profiling; Glycine; Immunohis | 2012 |
Different serine and glycine metabolism in patients with schizophrenia receiving clozapine.
Topics: Adult; Aged; Antipsychotic Agents; Clozapine; Excitatory Amino Acids; Female; Glycine; Humans; Male; | 2012 |
Biological perspectives: the role of glutamate in schizophrenia and its treatment.
Topics: Antipsychotic Agents; Dopamine; Excitatory Amino Acid Agonists; gamma-Aminobutyric Acid; Glutamic Ac | 2012 |
Reduction in phencyclidine induced sensorimotor gating deficits in the rat following increased system xc⁻ activity in the medial prefrontal cortex.
Topics: Acetylcysteine; Amino Acid Transport System y+; Amino Acid Transport Systems, Acidic; Animals; Benzo | 2013 |
No correlation between plasma NMDA-related glutamatergic amino acid levels and cognitive function in medicated patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Alanine; Antipsychotic Agents; Basal Ganglia Diseases; Biomarkers; Brief Ps | 2012 |
Allelic variation in the human prodynorphin gene promoter and schizophrenia.
Topics: Alleles; Case-Control Studies; Enkephalins; Genetic Variation; Genotype; Glycine; Humans; Italy; Pol | 2002 |
[Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Topics: Aged; Alleles; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Gene Frequency; Genetic Varia | 2003 |
Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.
Topics: Adolescent; Adult; Age Factors; Biomarkers; Brief Psychiatric Rating Scale; Chromatography, High Pre | 2003 |
[Hippuric acid excretion and disponibility of glycocoll in schizophrenic patients].
Topics: Glycine; Hippurates; Humans; Schizophrenia | 1952 |
URINARY TRYPTAMINE AND INDOLE-3-ACETIC ACID EXCRETION BY SCHIZOPHRENIC PATIENTS: USE OF THE TRYPTAMINE/INDOLE ACETIC ACID RATIO AS AN INDEX OF MONOAMINE OXIDASE INHIBITION.
Topics: Amino Acids; Fluids and Secretions; Glutamine; Glycine; Histidine; Humans; Indoleacetic Acids; Indol | 1964 |
METHIONINE EFFECTS ON CHRONIC SCHIZOPHRENICS: PATIENTS TREATED WITH MONOAMINE OXIDASE INHIBITORS.
Topics: Biomedical Research; Drug Synergism; Drug Therapy; Glycine; Iproniazid; Isocarboxazid; Mental Disord | 1965 |
Catechol-o-methyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression.
Topics: Adult; Alanine; Analysis of Variance; Bipolar Disorder; Blotting, Southern; Case-Control Studies; Ca | 2004 |
Schizophrenia, dissociative anaesthesia and near-death experience; three events meeting at the NMDA receptor.
Topics: Anesthetics, Dissociative; Animals; Brain; Death; Glutamic Acid; Glycine; Humans; Models, Biological | 2004 |
NOTCH4 gene haplotype is associated with schizophrenia in African Americans.
Topics: Alleles; Black or African American; Chi-Square Distribution; Cysteine; Diagnostic and Statistical Ma | 2004 |
Support for RGS4 as a susceptibility gene for schizophrenia.
Topics: Adult; Alanine; Alleles; Case-Control Studies; Chi-Square Distribution; Diagnostic and Statistical M | 2004 |
The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors.
Topics: Acetates; Amino Acid Transport Systems, Neutral; Animals; Antipsychotic Agents; Glycine; Glycine Pla | 2004 |
Effects of typical and atypical antipsychotics on human glycine transporters.
Topics: Amino Acid Transport Systems, Neutral; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chlori | 2004 |
Modulation of striatal dopamine release by glycine transport inhibitors.
Topics: Amino Acid Transport Systems, Neutral; Animals; Biphenyl Compounds; Corpus Striatum; Dopamine; Excit | 2005 |
Habit learning and the genetics of the dopamine D3 receptor: evidence from patients with schizophrenia and healthy controls.
Topics: Adult; Analysis of Variance; Cues; DNA Mutational Analysis; Female; Glycine; Habits; Humans; Learnin | 2005 |
Age at onset of schizophrenia: interaction between brain-derived neurotrophic factor and dopamine D3 receptor gene variants.
Topics: Adult; Age of Onset; Brain-Derived Neurotrophic Factor; Chi-Square Distribution; Female; Genetic Var | 2005 |
Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type.
Topics: Adult; Amino Acids; Antipsychotic Agents; Clozapine; Female; Glycine; Homocysteine; Humans; Male; Mi | 2005 |
Examination of the zinc transporter gene, SLC39A12.
Topics: Alleles; Brain; Cation Transport Proteins; Exons; Genotype; Glycine; Humans; Mutation, Missense; Ref | 2006 |
Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile.
Topics: Animals; Anxiety Disorders; Attention; Avoidance Learning; Cognition; Disease Models, Animal; Excita | 2006 |
Homozygosity of the interleukin-10 receptor 1 G330R allele is associated with schizophrenia.
Topics: Alleles; Arginine; Case-Control Studies; Female; Gene Frequency; Genetic Linkage; Genotype; Glycine; | 2007 |
No association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and schizophrenia in a Spanish sample.
Topics: Case-Control Studies; Gene Frequency; Genetic Linkage; Genotype; Glycine; Humans; Polymorphism, Sing | 2007 |
High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients.
Topics: Adult; Blinking; Chronic Disease; Electromyography; Female; Glutamic Acid; Glycine; Humans; Inhibiti | 2007 |
Involvement of a dysfunctional dopamine-D1/N-methyl-d-aspartate-NR1 and Ca2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Ki | 2007 |
Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine.
Topics: Animals; Behavior, Animal; Cebus; Disease Models, Animal; Dose-Response Relationship, Drug; Female; | 2007 |
Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia.
Topics: Amphetamine; Animals; Anticonvulsants; Anxiety; Autoreceptors; Benzoates; Brain; Central Nervous Sys | 2007 |
No association between the DRD3 Ser9Gly polymorphism and schizophrenia.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Diagnostic and Statistical Manual of Mental Disor | 2008 |
Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Amino Acids; Analysis of Variance; Animals; Behavior, Anima | 2008 |
DAOA ARG30LYS and verbal memory function in schizophrenia.
Topics: Adolescent; Adult; Arginine; Carrier Proteins; Female; Glycine; Humans; Intracellular Signaling Pept | 2007 |
Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia.
Topics: Age of Onset; Brain-Derived Neurotrophic Factor; Female; Genetic Variation; Glycine; Humans; Male; R | 2007 |
The Ser9Gly polymorphism of the dopamine D3 receptor gene and risk of schizophrenia: an association study and a large meta-analysis.
Topics: Adult; Alleles; Case-Control Studies; China; Female; Gene Frequency; Genetic Predisposition to Disea | 2008 |
Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia.
Topics: Amino Acid Transport System A; Animals; Antipsychotic Agents; Blotting, Western; Cerebellum; Control | 2008 |
Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients.
Topics: Antipsychotic Agents; Base Sequence; Case-Control Studies; Clozapine; DNA Primers; Glycine; Polymorp | 2009 |
The association of genotypic combination of the DRD3 and BDNF polymorphisms on the adhesio interthalamica and medial temporal lobe structures.
Topics: Adolescent; Adult; Brain-Derived Neurotrophic Factor; Dominance, Cerebral; Female; Genetic Predispos | 2008 |
Schizophrenia-like psychosis caused by a metabolic disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Diagnosis, Differential; Female; Glycine; Humans; Porphyria | 1980 |
Elevation of choline and glycine in red blood cells of psychiatric patients due to lithium treatment.
Topics: Adult; Affective Disorders, Psychotic; Choline; Erythrocytes; Female; Glycine; Humans; Lithium; Male | 1981 |
Dopamine D4 receptor variant, D4GLYCINE194, in Africans, but not in Caucasians: no association with schizophrenia.
Topics: Adult; Africa; Amino Acid Sequence; Base Sequence; Black People; Brain; DNA; Exons; Female; Genetic | 1994 |
Neuroleptic effects on serine and glycine metabolism.
Topics: Adult; Animals; Antipsychotic Agents; Brain; Cytosol; Female; Fluphenazine; Glycine; Glycine Hydroxy | 1993 |
Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis.
Topics: Adult; Aged; Brain Mapping; Cerebral Cortex; Chronic Disease; Female; Glutamates; Glutamic Acid; Gly | 1994 |
Serine and glycine metabolism in schizophrenic patients.
Topics: Adult; Glycine; Glycine Hydroxymethyltransferase; Humans; Male; N-Methylaspartate; Schizophrenia; Se | 1993 |
A familial/genetic study of plasma serine and glycine concentrations.
Topics: Dopamine; Female; gamma-Aminobutyric Acid; Glucose; Glutamates; Glycine; Humans; Internal-External C | 1993 |
Abnormal serine-glycine metabolism in the brains of schizophrenics.
Topics: Aged; Cytosol; Dominance, Cerebral; Female; Glycine; Humans; Male; Middle Aged; Mitochondria; Schizo | 1993 |
Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia.
Topics: Animals; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Glutamic Acid; Glycine; | 1995 |
Dopamine D3 receptor Gly9/Ser9 polymorphism and schizophrenia: no increased frequency of homozygosity in German familial cases.
Topics: Adult; Alleles; Codon, Terminator; DNA Mutational Analysis; Female; Gene Frequency; Germany; Glycine | 1996 |
Glycine therapy of schizophrenia: some caveats.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Glycine; Humans; Receptors, N-Methyl-D-Aspar | 1996 |
Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Depression; Dose-Response Relationship, Drug; Dru | 1996 |
A postmortem study of glycine and its potential precursors in chronic schizophrenics.
Topics: Adult; Aged; Brain Chemistry; Chromatography, High Pressure Liquid; Chronic Disease; Female; Glycine | 1996 |
Glycine therapy of schizophrenia.
Topics: Dose-Response Relationship, Drug; Glycine; Humans; Long-Term Care; Receptors, N-Methyl-D-Aspartate; | 1996 |
Further evidence of no association between Ser9Gly polymorphism of dopamine D3 receptor gene and schizophrenia.
Topics: Alleles; Asian People; Case-Control Studies; Female; Genotype; Glycine; Humans; Male; Middle Aged; P | 1997 |
Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse.
Topics: Animals; Cerebral Cortex; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; gamma-Aminobutyric | 1997 |
Gly(247)-->Asp proenkephalin A mutation is rare in schizophrenia populations.
Topics: Aspartic Acid; Enkephalins; Female; Glycine; Humans; Male; Mutation; Protein Precursors; Schizophren | 1997 |
The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response.
Topics: Alleles; Antipsychotic Agents; Child; Clozapine; Female; Genetic Carrier Screening; Genotype; Glycin | 1998 |
European Multicentre Association Study of Schizophrenia: a study of the DRD2 Ser311Cys and DRD3 Ser9Gly polymorphisms.
Topics: Alleles; Cystine; Gene Frequency; Genotype; Glycine; Humans; Polymorphism, Genetic; Receptors, Dopam | 1998 |
D-serine and the therapeutic challenge posed by the N-methyl-D-aspartate antagonist model of schizophrenia.
Topics: Glycine; Humans; N-Methylaspartate; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Serine | 1998 |
What is the role of glutamate in schizophrenia?
Topics: Cycloserine; Glutamic Acid; Glycine; Humans; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Schiz | 1999 |
Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Genotype; Glycine; Humans; Israel; Je | 1999 |
A hyperglycinergic rat model for the pathogenesis of schizophrenia: preliminary findings.
Topics: Animals; Animals, Newborn; Brain Chemistry; Cerebral Ventricles; Disease Models, Animal; Female; Gly | 1999 |
Inhibition of striatal dopamine release by glycine and glycyldodecylamide.
Topics: Aminoquinolines; Animals; Corpus Striatum; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amin | 2000 |
New style clinical trials in schizophrenia.
Topics: Antimetabolites; Clinical Trials as Topic; Cycloserine; Glycine; Humans; Research Design; Schizophre | 1999 |
Glycine reduces novelty- and methamphetamine-induced locomotor activity in neonatal ventral hippocampal damaged rats.
Topics: Animals; Disease Models, Animal; Glycine; Hippocampus; Hyperkinesis; Ibotenic Acid; Methamphetamine; | 2001 |
Chronic high-dose glycine nutrition: effects on rat brain cell morphology.
Topics: Adaptation, Physiological; Animals; Antibodies, Monoclonal; Astrocytes; Brain; Calcium Channels; Cel | 2001 |
Chronic high-dose glycine nutrition: effects on rat brain cell morphology.
Topics: Adaptation, Physiological; Animals; Antibodies, Monoclonal; Astrocytes; Brain; Calcium Channels; Cel | 2001 |
Chronic high-dose glycine nutrition: effects on rat brain cell morphology.
Topics: Adaptation, Physiological; Animals; Antibodies, Monoclonal; Astrocytes; Brain; Calcium Channels; Cel | 2001 |
Chronic high-dose glycine nutrition: effects on rat brain cell morphology.
Topics: Adaptation, Physiological; Animals; Antibodies, Monoclonal; Astrocytes; Brain; Calcium Channels; Cel | 2001 |
[Study of association between the ser-9-gly polymorphism of the D3 dopaminergic receptor and schizophrenia].
Topics: Case-Control Studies; Female; Gene Frequency; Genotype; Glycine; Humans; Male; Polymorphism, Genetic | 2001 |
NMDA-associated glycine binding site increases in schizophrenic brains.
Topics: Cerebral Cortex; Glycine; Humans; Radioligand Assay; Receptors, Glycine; Receptors, N-Methyl-D-Aspar | 1992 |
Glycine agonists in the treatment of schizophrenia?
Topics: Animals; Glycine; Humans; Mice; Rats; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 1992 |
Plasma serine in schizophrenics and controls measured by gas chromatography-mass spectrometry.
Topics: Adult; Antipsychotic Agents; Female; Gas Chromatography-Mass Spectrometry; Glycine; Humans; Male; Ps | 1991 |
Abnormal serine hydroxymethyl transferase activity in the temporal lobes of schizophrenics.
Topics: Adult; Female; Frontal Lobe; gamma-Aminobutyric Acid; Glycine; Glycine Hydroxymethyltransferase; Hum | 1990 |
An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics.
Topics: Adult; Chronic Disease; Drug Therapy, Combination; Fluphenazine; Glycine; Humans; Male; Psychiatric | 1990 |
Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Basal Ganglia Diseases; Benztropine; Chronic Disease; Cognitio | 1989 |
Cerebrospinal fluid amino acid concentrations in chronic schizophrenia.
Topics: Adult; Aged; Alanine; Amino Acids; Chronic Disease; Female; Glutamates; Glutamic Acid; Glutamine; Gl | 1987 |
Derangement of one-carbon metabolism in episodic schizoaffective psychoses.
Topics: Bipolar Disorder; Carbolines; Carbon; Glycine; Humans; Schizophrenia; Serine; Taurine | 1988 |
Glycine therapy of schizophrenia.
Topics: Glycine; Humans; Schizophrenia | 1988 |
Interconversion of serine and glycine is normal in psychotic patients.
Topics: Adult; Brain Chemistry; Glycine; Humans; Schizophrenia; Schizophrenia, Childhood; Serine | 1985 |
Medical Research Council Neurochemical Pharmacology Unit.
Topics: Aminobutyrates; Antidepressive Agents; Biogenic Amines; Brain; Carboxy-Lyases; Chlorpromazine; Cycli | 1974 |